
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5162906/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response to: â€~Correspondence on â€~Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng. Annals of the Rheumatic Diseases, 2023, 82, e167-e167.	0.5	4
2	Response to: â€~Correspondence on â€~EULAR definition of difficult-to-treat rheumatoid arthritis'' by Novella-Navarro <i>et al</i> . Annals of the Rheumatic Diseases, 2023, 82, e56-e56.	0.5	2
3	Correspondence on â€~Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment'. Annals of the Rheumatic Diseases, 2023, 82, e183-e183.	0.5	3
4	Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2023, 82, 763-772.	0.5	18
5	Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a <scp>52â€Week</scp> , Randomized, Controlled Trial. Arthritis Care and Research, 2022, 74, 451-460.	1.5	10
6	Response to: â€~Correspondence on â€~EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e174-e174.	0.5	14
7	Response to: â€~Comment on: â€~EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Gossec <i>et al</i> ' by Wei <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e139-e139.	0.5	30
8	Response to: †Reactive arthritis, a missing link: comment on the recent article from Sepriano <i>et al</i> ' by Zeidler and Hudson. Annals of the Rheumatic Diseases, 2022, 81, e41-e41.	0.5	0
9	Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension. Rheumatology, 2022, 61, 617-627.	0.9	3
10	Real-time <i>vs</i> static scoring in musculoskeletal ultrasonography in patients with inflammatory hand osteoarthritis. Rheumatology, 2022, 61, SI65-SI72.	0.9	2
11	Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: Oneâ€Year Results of a Doubleâ€Blind, Placeboâ€Controlled Study and Openâ€Label Extension. Arthritis and Rheumatology, 2022, 74, 70-80.	2.9	38
12	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 20-33.	0.5	104
13	Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. Journal of Rheumatology, 2022, 49, 133-141.	1.0	5
14	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis. Rheumatology, 2022, 61, 2054-2062.	0.9	4
15	<scp>Longa€lerm</scp> Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukinâ€23, Through Two Years: Results From a Phase <scp>III</scp> , Randomized, <scp>Doubleâ€Blind</scp> , <scp>Placeboâ€Controlled</scp> Study Conducted in <scp>Biologicâ€Naive</scp> Patients With Active Psoriatic Arthritis. Arthritis and Rheumatology, 2022,	2.9	41
16	74, 475-485. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years. Journal of Rheumatology, 2022, 49, 265-273.	1.0	16
17	Correspondence on "Reâ€examining remission definitions in rheumatoid arthritis: considering the <scp>28â€Joint</scp> Disease Activity Score, Câ€reactive protein level and patient global assessment―by Felson et al. ACR Open Rheumatology, 2022, 4, 271-272.	0.9	1
18	Reexamining remission definitions in rheumatoid arthritis: considering the 28â€joint Disease Activity Score, Câ€reactive protein level, and patient global assessment: comment on the article by Felson et al. Arthritis Care and Research, 2022, 74, 501-502.	1.5	0

#	Article	IF	CITATIONS
19	Measuring quality of life of patients with axial spondyloarthritis for economic evaluation. RMD Open, 2022, 8, e001955.	1.8	2
20	Associations between syndesmophytes and facet joint ankylosis in radiographic axial spondyloarthritis patients on low-dose CT over 2 years. Rheumatology, 2022, 61, 4722-4730.	0.9	3
21	Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. RMD Open, 2022, 8, e002138.	1.8	2
22	Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study. RMD Open, 2022, 8, e002174.	1.8	3
23	<i>Post hoc</i> analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Modern Rheumatology, 2022, , .	0.9	3
24	Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Annals of the Rheumatic Diseases, 2022, 81, 815-822.	0.5	88
25	MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2022, 81, 1243-1251.	0.5	22
26	How is early spondyloarthritis defined in the literature? Results from a systematic review. Seminars in Arthritis and Rheumatism, 2022, 55, 152032.	1.6	13
27	Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial. Annals of the Rheumatic Diseases, 2022, 81, 1392-1399.	0.5	9
28	Low-dose CT hounsfield units: a reliable methodology for assessing vertebral bone density in radiographic axial spondyloarthritis. RMD Open, 2022, 8, e002149.	1.8	6
29	Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Annals of the Rheumatic Diseases, 2022, 81, 1515-1523.	0.5	43
30	Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis. RMD Open, 2022, 8, e002250.	1.8	9
31	Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable. Rheumatology, 2021, 60, 638-648.	0.9	9
32	Use of multidimensional composite scores in rheumatology: parsimony versus subtlety. Annals of the Rheumatic Diseases, 2021, 80, 280-285.	0.5	17
33	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.5	158
34	Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort. Rheumatology, 2021, 60, 316-321.	0.9	9
35	Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. Journal of Rheumatology, 2021, 48, 188-197.	1.0	7
36	Efficacy and Safety of Guselkumab, an Interleukinâ€23p19–Specific Monoclonal Antibody, Through One Year in Biologicâ€Naive Patients With Psoriatic Arthritis. Arthritis and Rheumatology, 2021, 73, 604-616.	2.9	48

#	Article	IF	CITATIONS
37	Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. Annals of the Rheumatic Diseases, 2021, 80, 293-303.	0.5	32
38	EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases, 2021, 80, 31-35.	0.5	224
39	Two different invitation approaches for consecutive rounds of a Delphi survey led to comparable final outcome. Journal of Clinical Epidemiology, 2021, 129, 31-39.	2.4	41
40	Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies. Rheumatology, 2021, 60, 1708-1716.	0.9	4
41	Comment on: Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable: reply. Rheumatology, 2021, 60, e71-e72.	0.9	1
42	Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors. Rheumatology, 2021, 60, 461-462.	0.9	10
43	Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR. Arthritis Research and Therapy, 2021, 23, 43.	1.6	12
44	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). Annals of the Rheumatic Diseases, 2021, 80, 840-847.	0.5	31
45	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open, 2021, 7, e001450.	1.8	64
46	Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open, 2021, 7, e001512.	1.8	42
47	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Annals of the Rheumatic Diseases, 2021, 80, 727-738.	0.5	76
48	Radiographic sacroiliitis progression in axial spondyloarthritis: central reading of 5 year follow-up data from the Assessment of SpondyloArthritis international Society cohort . Rheumatology, 2021, 60, 2478-2480.	0.9	7
49	A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. Journal of Rheumatology, 2021, 48, 1259-1267.	1.0	8
50	Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy. RMD Open, 2021, 7, e001525.	1.8	16
51	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. Rheumatology, 2021, 60, 4778-4789.	0.9	44
52	The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study. Lancet Rheumatology, The, 2021, 3, e284-e293.	2.2	9
53	Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. Journal of Rheumatology, 2021, 48, 1663-1671.	1.0	10
54	Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases, 2021, 80, 1004-1013.	0.5	124

#	Article	IF	CITATIONS
55	POS0918â€EVALUATION OF SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING IXEKIZUMAB THERAPY OVER 2 YEARS. Annals of the Rheumatic Diseases, 2021, 80, 720.1-720.	0.5	1
56	Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Annals of the Rheumatic Diseases, 2021, 80, 1436-1444.	0.5	58
57	POS0198â€EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Annals of the Rheumatic Diseases, 2021, 80, 314.2-315.	IN 0.5	9
58	POS0182â€MINIMAL CLINICALLY IMPORTANT IMPROVEMENT (MCII) AND PATIENT ACCEPTABLE SYMPTOM STA (PASS) FOR PAIN AND FUNCTION INSTRUMENTS IN HAND OSTEOARTHRITIS (OA). Annals of the Rheumatic Diseases, 2021, 80, 304.2-305.	.TE 0.5	1
59	OP0227â€EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Annals of the Rheumatic Diseases, 2021, 80, 137-138.	0.5	1
60	Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort. Arthritis and Rheumatology, 2021, 73, 1211-1219.	2.9	25
61	POS0944â€AGE AT ONSET IN AXIAL SPONDYLOARTHRITIS AROUND THE WORLD: DATA FROM THE INTERNATIONAL ASAS-PERSPA STUDY. Annals of the Rheumatic Diseases, 2021, 80, 735.1-735.	0.5	1
62	OP0251â€DATA-DRIVEN DEFINITIONS BASED ON INFLAMMATORY LESIONS FOR A POSITIVE MRI OF THE SPINE CONSISTENT WITH AXIAL SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 153.1-153.	0.5	0
63	Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission. JAMA - Journal of the American Medical Association, 2021, 325, 1755.	3.8	17
64	POS0032â€SCORING MRI STRUCTURAL LESIONS IN SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: HOW MANY SLICES ARE OPTIMAL?. Annals of the Rheumatic Diseases, 2021, 80, 221.1-221.	0.5	0
65	POS0954â€QUALITY OF LIFE IN CHRONIC BACK PAIN PATIENTS, A 2-YEAR COMPARISON BETWEEN PATIENTS WITH AND WITHOUT A DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS: DATA FROM THE SPONDYLOARTHRITIS CAUGHT EARLY COHORT. Annals of the Rheumatic Diseases, 2021, 80, 741-741.	0.5	1
66	POS0226â€BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY. Annals of the Rheumatic Diseases, 2021, 80, 332-333.	0.5	2
67	OP0047â€IDENTIFICATION OF CLINICAL PHENOTYPES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS ACCORDING TO PERIPHERAL MUSCULOSKELETAL MANIFESTATIONS: A CLUSTER ANALYSIS IN THE INTERNATIONAL ASAS-PERSPA STUDY. Annals of the Rheumatic Diseases, 2021, 80, 24,2-25.	0.5	0
68	POS0975â€CLINICAL CHARACTERISTICS OF NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN ASIAN COUNTRIES COMPARED TO OTHER REGIONS: RESULTS OF THE INTERNATIONAL CROSS-SECTIONAL ASAS-COMOSPA STUDY. Annals of the Rheumatic Diseases, 2021, 80, 753.2-754.	0.5	0
69	POS1027â€EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE p19-SUBUI OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÃVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 2021. 80, 783-784.	NIT 0.5	4
70	Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort. RMD Open, 2021, 7, e001685.	1.8	6
71	Joint tenderness and ultrasound inflammation in DMARD-na \tilde{A} ve patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2021, 80, 1493-1494.	0.5	2
72	Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference. RMD Open, 2021, 7, e001654.	1.8	16

#	Article	IF	CITATIONS
73	Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open, 2021, 7, e001600.	1.8	18
74	The ASAS-OMERACT core domain set for axial spondyloarthritis. Seminars in Arthritis and Rheumatism, 2021, 51, 1342-1349.	1.6	35
75	Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey. Journal of Rheumatology, 2021, 48, 1810-1814.	1.0	3
76	Lifestyle Factors and Disease Activity over Time in Early Axial Spondyloarthritis - The SPondyloArthritis Caught Early (SPACE) Cohort. Journal of Rheumatology, 2021, , jrheum.210046.	1.0	3
77	Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. RMD Open, 2021, 7, e001752.	1.8	11
78	Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process. Seminars in Arthritis and Rheumatism, 2021, 51, 1311-1319.	1.6	6
79	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatology, The, 2021, 3, e715-e723.	2.2	53
80	Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open, 2021, 7, e001511.	1.8	12
81	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the Rheumatic Diseases, 2021, 80, 848-858.	0.5	123
82	Biomechanical Factors May Be the Main Contributor to Entheseal Changes in Normal Adults. Journal of Rheumatology, 2021, 48, 618-619.	1.0	3
83	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. RMD Open, 2021, 7, e001728.	1.8	5
84	Dose reduction and discontinuation of biologic and targeted syntheticÂdisease-modifying anti-rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity. The Cochrane Library, 2021, 2021, .	1.5	0
85	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Therapeutic Advances in Musculoskeletal Disease. 2021, 13, 1759720X2110579.	1.2	30
86	Axial spondyloarthritis. Annals of the Rheumatic Diseases, 2021, 80, 1511-1521.	0.5	118
87	Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis. RMD Open, 2021, 7, e001839.	1.8	3
88	Non-steroidal anti-inflammatory drugs for acute gout. The Cochrane Library, 2021, 2021, CD010120.	1.5	7
89	Associations of lumbar scoliosis with presentation of suspected early axial spondyloarthritis. Seminars in Arthritis and Rheumatism, 2020, 50, 48-53.	1.6	3
90	Self-reported painful joint count and assessor-reported tender joint count as instruments to assess pain in hand osteoarthritis. Rheumatology, 2020, 59, 1094-1098.	0.9	4

#	Article	IF	CITATIONS
91	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology, 2020, 59, 1325-1334.	0.9	40
92	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. Journal of Rheumatology, 2020, 47, 809-819.	1.0	16
93	Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. Rheumatology, 2020, 59, 292-302.	0.9	43
94	Spinal-pelvic orientation: potential effect on the diagnosis of spondyloarthritis. Rheumatology, 2020, 59, 84-89.	0.9	4
95	Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study. Rheumatology, 2020, 59, 1632-1639.	0.9	3
96	Association of lumbosacral transitional vertebra and sacroiliitis in patients with inflammatory back pain suggesting axial spondyloarthritis. Rheumatology, 2020, 59, 1679-1683.	0.9	5
97	Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study. Health and Quality of Life Outcomes, 2020, 18, 4.	1.0	10
98	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Annals of the Rheumatic Diseases, 2020, 79, 176-185.	0.5	76
99	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet, The, 2020, 395, 53-64.	6.3	138
100	P217 Efficacy and safety of filgotinib for patients with RA naÃ⁻ve to MTX therapy: FINCH3 primary outcome results. Rheumatology, 2020, 59, .	0.9	0
101	P250 Effect of secukinumab on radiographic progression through 2 years in patients with active PsA: end-of-study results from a Phase 3 study. Rheumatology, 2020, 59, .	0.9	0
102	Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT). Arthritis Research and Therapy, 2020, 22, 225.	1.6	8
103	P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results. Rheumatology, 2020, 59, .	0.9	1
104	Which imaging outcomes for axSpA are most sensitive to change? A 5‥ear analysis of The DESIR Cohort. Arthritis Care and Research, 2020, , .	1.5	5
105	Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry. RMD Open, 2020, 6, e001277.	1.8	8
106	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open, 2020, 6, e001374.	1.8	36
107	Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. RMD Open, 2020, 6, e001249.	1.8	8
108	Measuring Outcomes in Axial Spondyloarthritis. Arthritis Care and Research, 2020, 72, 47-71.	1.5	11

#	Article	IF	CITATIONS
109	Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis. Rheumatology, 2020, 59, 3990-3992.	0.9	3
110	Inflammation of the sacroiliac joints and spine on MRI predicts structural changes on MRI in axial spondyloarthritis: 5â€year data from DESIR. Arthritis Care and Research, 2020, , .	1.5	4
111	No relationship between bone mineral density and syndesmophyte formation at the same level in the lumbar spine of patients with radiographic axial Spondyloarthritis. RMD Open, 2020, 6, e001391.	1.8	6
112	5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort. RMD Open, 2020, 6, e001093.	1.8	10
113	Facet joint ankylosis in r-axSpA: detection and 2-year progression on whole spine low-dose CT and comparison with syndesmophyte progression. Rheumatology, 2020, 59, 3776-3783.	0.9	19
114	Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Annals of the Rheumatic Diseases, 2020, 79, 920-928.	0.5	53
115	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 2020, 79, 778-786.	0.5	104
116	Reliability of Magnetic Resonance Imaging (MRI) Scoring of the Metatarsophalangeal Joints of the Foot according to the Rheumatoid Arthritis MRI Score. Journal of Rheumatology, 2020, 47, 1165-1173.	1.0	10
117	Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria. Annals of the Rheumatic Diseases, 2020, 79, 935-942.	0.5	14
118	Do Illness Perceptions and Coping Strategies Change Over Time in Patients Recently Diagnosed With Axial Spondyloarthritis?. Journal of Rheumatology, 2020, 47, 1752-1759.	1.0	9
119	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 700.1-712.	0.5	609
120	Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE. Rheumatology and Therapy, 2020, 7, 581-599.	1.1	13
121	Do Smoking and Socioeconomic Factors Influence Imaging Outcomes in Axial Spondyloarthritis? Five‥ear Data From the DESIR Cohort. Arthritis and Rheumatology, 2020, 72, 1855-1862.	2.9	19
122	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 760-770.	0.5	205
123	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Annals of the Rheumatic Diseases, 2020, 79, 453-459.	0.5	43
124	Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. Annals of the Rheumatic Diseases, 2020, 79, 464-471.	0.5	14
125	Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. PLoS ONE, 2020, 15, e0230268.	1.1	17
126	Integrated longitudinal analysis does not compromise precision and reduces bias in the study of imaging outcomes: A comparative 5-year analysis in the DESIR cohort. Seminars in Arthritis and Rheumatism, 2020, 50, 1394-1399.	1.6	5

#	Article	IF	CITATIONS
127	Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2020, 395, 1126-1136.	6.3	206
128	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. Journal of Rheumatology, 2020, 47, 796-808.	1.0	3
129	Development of classification criteria for hand osteoarthritis: comparative analyses of persons with and without hand osteoarthritis. RMD Open, 2020, 6, e001265.	1.8	14
130	Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Research and Therapy, 2020, 22, 18.	1.6	29
131	Ixekizumab treatment of biologic-naÃ ⁻ ve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology, 2020, 59, 2774-2784.	0.9	31
132	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 744-759.	0.5	167
133	Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. Trials, 2020, 21, 90.	0.7	14
134	Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis. Rheumatology, 2020, 59, 2550-2555.	0.9	14
135	What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. Annals of the Rheumatic Diseases, 2020, 79, 324-331.	0.5	41
136	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.5	1,860
137	Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases, 2020, 79, 595-604.	0.5	91
138	P242 CZP improves work and household productivity and social participation over 1 year of treatment in patients with non-radiographic axSpA. Rheumatology, 2020, 59, .	0.9	2
139	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2020, 79, 193-201.	0.5	59
140	Treatment-resistant synovitis and radiographic progression are increased in elderly-onset rheumatoid arthritis patients: findings from a prospective observational longitudinal early arthritis cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 735-743.	1.6	15
141	FRIO317â€CONSENSUS DEFINITIONS FOR MRI LESIONS IN THE SPINE OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: FIRST ANALYSIS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY CLASSIFICATION COHORT. Annals of the Rheumatic Diseases, 2020, 79, 749.2-750.	0.5	2
142	FRI0335â€THE EFFECT OF TOFACITINIB ON RESIDUAL PAIN IN PATIENTS WITH PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 760-761.	0.5	16
143	FRI0047â€STRATEGIES REGARDING GOAL SETTING AND SELF-MANAGEMENT IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2020 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 2020, 79, 599.2-599.	0.5	1
144	FRI0302â€WHAT IS THE IMPACT OF DISCREPANCY BETWEEN CENTRAL AND LOCAL READERS IN EVALUATION C MRI SCANS ON THE CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS? DATA FROM THE ASAS CLASSIFICATION COHORT STUDY Annals of the Rheumatic Diseases, 2020, 79, 740, 2-741)F 0.5	0

#	Article	IF	CITATIONS
145	AB0824â€WHICH PARAMETERS ARE RELEVANT IN THE IDENTIFYING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS? – RESULTS OF A SURVEY AMONG ASAS AND GRAPPA MEMBERS. Annals of the Rheumatic Diseases, 2020, 79, 1715.1-1716.	0.5	2
146	OP0105â€EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY. Annals of the Rheumatic Diseases, 2020, 79, 68-69.	D 0.5	0
147	OP0103â€DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?. Annals of the Rheumatic Diseases, 2020, 79, 66.1-67.	N 0.5	1
148	OP0315â€WHICH RESPONSE OR STATUS CRITERION DISCRIMINATES BEST IN AXSPA?. Annals of the Rheumatic Diseases, 2020, 79, 194.1-195.	0.5	0
149	SAT0052â€THERAPEUTIC STRATEGIES IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2020 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 957-957.	0.5	3
150	OP0078â€MAPPING FROM THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS) TO EQ5D IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 52.1-53.	0.5	0
151	SAT0384â€REPLACEMENT OF RADIOGRAPHIC SACROILITIS BY MRI STRUCTURAL LESIONS: WHAT IS THE IMPAC ON CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS IN THE ASAS CLASSIFICATION COHORT?. Annals of the Rheumatic Diseases, 2020, 79, 1140.2-1141.	T 0.5	0
152	SAT0587â€MACHINE-LEARNING DERIVED ALGORITHMS FOR OUTCOMES PREDICTION IN RHEUMATIC DISEASES APPLICATION TO RADIOGRAPHIC PROGRESSION IN EARLY AXIAL SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1252.2-1253.	5: 0.5	0
153	Determinants of the physician global assessment of disease activity and influence of contextual factors in early axial spondyloarthritis Arthritis Care and Research, 2020, , .	1.5	1
154	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. Clinical and Experimental Rheumatology, 2020, 38, 848-857.	0.4	6
155	Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology, 2019, 58, 388-400.	0.9	93
156	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, e109-e109.	0.5	35
157	Response to: †Inconsistency between supplement and article?' by Babaoglu H. Annals of the Rheumatic Diseases, 2019, 78, e85-e85.	0.5	1
158	Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Annals of the Rheumatic Diseases, 2019, 78, 1545-1549.	0.5	71
159	Low specificity but high sensitivity of inflammatory back pain criteria in rheumatology settings in Europe: confirmation of findings from a German cohort study. Annals of the Rheumatic Diseases, 2019, 78, 1605-1606.	0.5	15
160	Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet, The, 2019, 394, 2108-2117.	6.3	223
161	Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS. Arthritis Research and Therapy, 2019, 21, 225.	1.6	6
162	079 Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csDMARDs in patients with rheumatoid arthritis. Rheumatology, 2019, 58, .	0.9	0

#	Article	IF	CITATIONS
163	262 Secukinumab demonstrates rapid and sustained efficacy in ankylosing spondylitis patients with normal or elevated baseline C-reactive protein levels: pooled analysis of two Phase 3 studies. Rheumatology, 2019, 58, .	0.9	0
164	E098 Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: results from the 48-week run-in part of a 96-week study (NCT02505542). Rheumatology, 2019, 58, .	0.9	0
165	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Annals of the Rheumatic Diseases, 2019, 78, 1305-1319.	0.5	95
166	Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. Cell Reports, 2019, 28, 2455-2470.e5.	2.9	241
167	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2019, 78, 1550-1558.	0.5	171
168	The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review. Rheumatology, 2019, 58, 1907-1922.	0.9	21
169	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twentyâ€Four–Month, Phase <scp>III</scp> Study. Arthritis and Rheumatology, 2019, 71, 878-891.	2.9	64
170	Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. RMD Open, 2019, 5, e000898.	1.8	14
171	Spinal radiographic progression over 2Âyears in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Arthritis Research and Therapy, 2019, 21, 142.	1.6	31
172	081 Long-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9,000 patient-years of follow-up. Rheumatology, 2019, 58, .	0.9	1
173	Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE) Tj ETQq1 1 0.7 2019, 78, 899-907.	784314 rgB	BT /Overlock
174	A Fiftyâ€Two–Week, Randomized, Placeboâ€Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 1101-1111.	2.9	71
175	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. Journal of Rheumatology, 2019, 46, 1089-1096.	1.0	37
176	Percentage of progressors in imaging: can we ignore regressors?. RMD Open, 2019, 5, e000848.	1.8	12
177	Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA). Annals of the Rheumatic Diseases, 2019, 78, 486-493.	0.5	24
178	Measuring spinal mobility in early axial spondyloarthritis: does it matter?. Rheumatology, 2019, 58, 1597-1606.	0.9	16
179	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2019, 78, 761-772.	0.5	219
180	ls a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. Rheumatology, 2019, 58, 1649-1654.	0.9	23

#	Article	IF	CITATIONS
181	Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ). Journal of Rheumatology, 2019, 46, 1192-1197.	1.0	23
182	Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World. Journal of Rheumatology, 2019, 46, 896-903.	1.0	14
183	HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort. Genes and Immunity, 2019, 20, 671-677.	2.2	0
184	Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. Arthritis Care and Research, 2019, 71, 1317-1325.	1.5	41
185	Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data. Seminars in Arthritis and Rheumatism, 2019, 49, 218-221.	1.6	1
186	Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI. RMD Open, 2019, 5, e000872.	1.8	6
187	FRI0397â€EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE. , 2019, , .		0
188	OP0231â€DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY., 2019,,.		1
189	SAT0125â€LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP., 2019, , .		1
190	AB1321â€PSYCHOMETRIC PROPERTIES OF THE ASAS HEALTH INDEX IN PATIENTS WITH ACTIVE AS/RADIOGRAI AXIAL SPA WHO HAVE PRIOR INADEQUATE RESPONSE/INTOLERANCE TO TNF INHIBITORS IN A PHASE 3 TRIAL. , 2019, , .	νніс	0
191	AB0763â€SAFETY OF ABATACEPT TREATMENT OVER 2 YEARS IN A PHASE III ACTIVE PSORIATIC ARTHRITIS RANDOMIZED TRIAL (ASTRAEA). , 2019, , .		0
192	THU0358â€DEVELOPMENT OF A SET OF ASAS QUALITY STANDARDS FOR ADULTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
193	LB0001â€EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQU RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS. , 2019, , .	ATE	15
194	LB0003â€EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS NAÃ⁻VE TO METHOTREXATE THERAPY: FINCH3 PRIMARY OUTCOME RESULTS. , 2019, , .		5
195	Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open, 2019, 5, e000887.	1.8	27
196	Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open, 2019, 5, e001108.	1.8	77
197	Three Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 258-270.	2.9	237
198	Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?. Arthritis and Rheumatology, 2019, 71, 382-391.	2.9	19

#	Article	IF	CITATIONS
199	Is active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohorts. Rheumatology, 2019, 58, 798-802.	0.9	11
200	Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 413-420.	0.5	115
201	Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. Rheumatology, 2019, 58, 997-1005.	0.9	16
202	Report from the Hand Osteoarthritis Working Group at OMERACT 2018: Update on Core Instrument Set Development. Journal of Rheumatology, 2019, 46, 1183-1187.	1.0	10
203	Spinal Radiographic Progression in Early Axial Spondyloarthritis: Fiveâ€Year Results From the <scp>DESIR</scp> Cohort. Arthritis Care and Research, 2019, 71, 1678-1684.	1.5	38
204	Alternative diagnoses in patients with chronic back pain not diagnosed with axial spondyloarthritis: data from the SPACE cohort. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212175.	0.5	3
205	Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain. Arthritis and Rheumatology, 2018, 70, 1042-1048.	2.9	175
206	Pathophysiology of axial spondyloarthritis: Consensus and controversies. European Journal of Clinical Investigation, 2018, 48, e12913.	1.7	32
207	Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Annals of the Rheumatic Diseases. 2018. 77. annrheumdis-2017-212565.	0.5	29
208	Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (<scp>RMD</scp> s) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (<scp>EULAR</scp>) and the American College of Rheumatology (<scp>ACR</scp>). Arthritis and Rheumatology, 2018, 70, 826-831.	2.9	21
209	The Impact of Ultrasound on the Use and Efficacy of Intraarticular Glucocorticoid Injections in Early Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1192-1199.	2.9	18
210	"Big Data―in Rheumatology. Rheumatic Disease Clinics of North America, 2018, 44, 307-315.	0.8	12
211	The Impact of Illness Perceptions and Coping on the Association Between Back Pain and Health Outcomes in Patients Suspected of Having Axial Spondyloarthritis: Data From the <scp>SP</scp> ondyloArthritis Caught Early Cohort. Arthritis Care and Research, 2018, 70, 1829-1839.	1.5	21
212	Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Annals of the Rheumatic Diseases, 2018, 77, 1539-1540.	0.5	159
213	Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. Journal of Rheumatology, 2018, 45, 506-512.	1.0	31
214	Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis. Annals of the Rheumatic Diseases, 2018, 77, 221-227.	0.5	40
215	Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Annals of the Rheumatic Diseases, 2018, 77, 699-705.	0.5	98
216	Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the <scp>US</scp> â€Based Corrona Registry. Arthritis Care and Research, 2018, 70, 1661-1670.	1.5	53

#	Article	IF	CITATIONS
217	Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). Journal of Rheumatology, 2018, 45, 367-377.	1.0	102
218	Response to: â€~Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis' by Chevreau <i>et al</i> . Annals of the Rheumatic Diseases, 2018, 77, e85-e85.	0.5	1
219	Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial. Arthritis Research and Therapy, 2018, 20, 61.	1.6	32
220	lmaging of the sacroiliac joints is important for diagnosing early axial spondyloarthritis but not all-decisive. Rheumatology, 2018, 57, 1173-1179.	0.9	12
221	Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212687.	0.5	193
222	Validity, reliability, responsiveness and feasibility of four hand mobility measures in hand osteoarthritis. Rheumatology, 2018, 57, 525-532.	0.9	13
223	4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open, 2018, 4, e000582.	1.8	34
224	Impact of replacing radiographic sacroiliitis by magnetic resonance imaging structural lesions on the classification of patients with axial spondyloarthritis. Rheumatology, 2018, 57, 1186-1193.	0.9	11
225	In Early Axial Spondyloarthritis, Increasing Disease Activity Is Associated with Worsening of Health-related Quality of Life over Time. Journal of Rheumatology, 2018, 45, 779-784.	1.0	10
226	The influence of discrepant imaging judgements on the classification of axial spondyloarthritis is limited: a replication in the SpondyloArthritis Caught Early (SPACE) cohort. Annals of the Rheumatic Diseases, 2018, 77, e1-e1.	0.5	6
227	In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort. Annals of the Rheumatic Diseases, 2018, 77, 470-472.	0.5	8
228	How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. Annals of the Rheumatic Diseases, 2018, 77, 782-783.	0.5	18
229	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.5	484
230	Social Role Participation and Satisfaction With Life: A Study Among Patients With Ankylosing Spondylitis and Population Controls. Arthritis Care and Research, 2018, 70, 600-607.	1.5	15
231	Should radiographic progression still be used as outcome in RA?. Clinical Immunology, 2018, 186, 79-81.	1.4	16
232	An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. Annals of the Rheumatic Diseases, 2018, 77, 124-127.	0.5	51
233	TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Annals of the Rheumatic Diseases, 2018, 77, 63-69.	0.5	220
234	Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2018, 77, 405-411.	0.5	34

#	Article	IF	CITATIONS
235	Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study. Journal of Rheumatology, 2018, 45, 206-212.	1.0	31
236	Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. Journal of Rheumatology, 2018, 45, 177-187.	1.0	18
237	Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. Annals of the Rheumatic Diseases, 2018, 77, 293-299.	0.5	71
238	Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. Annals of the Rheumatic Diseases, 2018, 77, 371-377.	0.5	48
239	Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study. Arthritis Care and Research, 2018, 70, 1257-1262.	1.5	52
240	Employment and the role of personal factors among patients with ankylosing spondylitis: a Dutch cross-sectional case-control study. RMD Open, 2018, 4, e000680.	1.8	12
241	Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. RMD Open, 2018, 4, e000749.	1.8	30
242	Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. RMD Open, 2018, 4, e000755.	1.8	15
243	Validity of the rheumatoid arthritis MRI score applied to the forefeet using the OMERACT filter: a systematic literature review. RMD Open, 2018, 4, e000796.	1.8	7
244	THU0246â€Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified disease activity index for psoriatic arthritis (DAPSA) based on 28 joints?. , 2018, , .		1
245	Response to: †The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies' by Tillet <i>et al</i> . Annals of the Rheumatic Diseases, 2018, 77, e24-e24.	0.5	1
246	LB0001â€Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study. , 2018, , .		6
247	Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. RMD Open, 2018, 4, e000766.	1.8	16
248	Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open, 2018, 4, e000752.	1.8	37
249	Validation and reliability of translation of the ASAS Health Index in a Colombian Spanish-speaking population with spondyloarthritis. Clinical Rheumatology, 2018, 37, 3063-3068.	1.0	9
250	Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?. Annals of the Rheumatic Diseases, 2018, 77, 1736-1741.	0.5	30
251	Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort. Arthritis Research and Therapy, 2018, 20, 218.	1.6	41
252	Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry. Rheumatology and Therapy, 2018, 5, 537-550.	1.1	13

#	Article	IF	CITATIONS
253	Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?. RMD Open, 2018, 4, e000648.	1.8	7
254	Which scoring method depicts spinal radiographic damage in early axial spondyloarthritis best? Five-year results from the DESIR cohort. Rheumatology, 2018, 57, 1991-2000.	0.9	11
255	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. The, 2018, 392, 2441-2451.	6.3	251
256	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet, The, 2018, 392, 2378-2387.	6.3	198
257	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Annals of the Rheumatic Diseases, 2018, 77, 1705-1709.	0.5	83
258	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. Rheumatology and Therapy, 2018, 5, 341-353.	1.1	9
259	Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open, 2018, 4, e000662.	1.8	18
260	Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology, 2018, 57, 1390-1399.	0.9	42
261	Prevalence of degenerative changes and overlap with spondyloarthritis-associated lesions in the spine of patients from the DESIR cohort. RMD Open, 2018, 4, e000657.	1.8	28
262	Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes. Annals of the Rheumatic Diseases, 2018, 77, 1421-1425.	0.5	25
263	Frequency of Impaired Spinal Mobility in Patients with Chronic Back Pain Compared to Patients with Early Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 1643-1650.	1.0	11
264	OP0199â€Sustained remission of inflammation is associated with reduced structural damage on sacroiliac joint magnetic resonance imaging in patients with early axial spondyloarthritis: evidence to support the concept of treat-to-target. , 2018, , .		0
265	Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. Clinical Rheumatology, 2018, 37, 2381-2390.	1.0	26
266	Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort. Arthritis Research and Therapy, 2018, 20, 166.	1.6	16
267	Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. Rheumatology, 2018, 57, 2022-2031.	0.9	19
268	Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. Frontiers in Medicine, 2018, 5, 40.	1.2	26
269	Associations Between Cardiorespiratory Fitness and Arterial Stiffness in Ankylosing Spondylitis: A Cross-sectional Study. Journal of Rheumatology, 2018, 45, 1522-1525.	1.0	5
270	Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort. Arthritis Research and Therapy, 2018, 20, 38.	1.6	35

#	Article	IF	CITATIONS
271	Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology, 2018, 57, 1423-1431.	0.9	31
272	Performance of the Michigan Hand Outcomes Questionnaire in hand osteoarthritis. Osteoarthritis and Cartilage, 2018, 26, 1627-1635.	0.6	13
273	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. Arthritis Research and Therapy, 2018, 20, 174.	1.6	18
274	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Annals of the Rheumatic Diseases, 2018, 77, 1311-1317.	0.5	85
275	Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2018, 77, 1303-1310.	0.5	18
276	Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls. Annals of the Rheumatic Diseases, 2018, 77, 1290-1294.	0.5	21
277	Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study. RMD Open, 2018, 4, e000659.	1.8	9
278	OP0323â€Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? data from the spondyloarthritis caught early cohort. , 2018, , .		0
279	FRI0172â€Inflammation on mri of the sacroiliac joints is highly predictive of structural damage in axial spondyloarthritis patients in clinical practice: data from the asas and desir cohorts. , 2018, , .		0
280	FRI0174â€Spinal radiographic progression in early axial spa: 5-year data from the desir cohort. , 2018, , .		0
281	FRI0179â€Integrated longitudinal analysis increases precision and reduces bias: a comparative 5-year analysis in the desir cohort. , 2018, , .		0
282	FRI0171â€Which imaging outcomes for axspa are most sensitive to change? a 5-year analysis of the desir cohort. , 2018, , .		0
283	OP0244â€An asas-positive mri of the sacroiliac joints can also occur in healthy individuals, runners and women with postpartum back pain. , 2018, , .		1
284	THU0276â€Mri lesion definitions in axial spondyloarthritis: a consensus reappraisal from the assessments in spondyloarthritis international society (ASAS). , 2018, , .		1
285	OP0306â€Subcutaneous secukinumab inhibits radiographic progression in psoriatic arthritis: analysis by prior anti-tnf therapy and concomitant methotrexate use. , 2018, , .		0
286	FRI0175â€Rates and predictors of radiographic sacroiliitis progression after central reading in patients with axial spondyloarthritis from the asas cohort: a 5-year follow-up study. , 2018, , .		0
287	FRIO216â€Detection of structural lesions on t1 weighted mri versus radiography of the si joints in early axial spondyloarthritis: 2-year data. , 2018, , .		0
288	SAT0172â€Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csdmards in patients with rheumatoid arthritis. , 2018, , .		0

#	Article	IF	CITATIONS
289	The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis. Acta Reumatológica Portuguesa, 2018, 43, 52-60.	0.2	5
290	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. Journal of Rheumatology, 2017, 44, 1522-1528.	1.0	93
291	New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology, 2017, 56, kew390.	0.9	36
292	Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort. Annals of the Rheumatic Diseases, 2017, 76, 1086-1092.	0.5	28
293	Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases, 2017, 76, 1340-1347.	0.5	287
294	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Annals of the Rheumatic Diseases, 2017, 76, 79-87.	0.5	454
295	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1113-1136.	0.5	195
296	Prevalence and clinical significance of lumbosacral transitional vertebra (LSTV) in a young back pain population with suspected axial spondyloarthritis: results of the SPondyloArthritis Caught Early (SPACE) cohort. Skeletal Radiology, 2017, 46, 633-639.	1.2	13
297	Automatic Quantification of Radiographic Wrist Joint Space Width of Patients With Rheumatoid Arthritis. IEEE Transactions on Biomedical Engineering, 2017, 64, 2695-2703.	2.5	6
298	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2017, 76, 978-991.	0.5	1,220
299	Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naà ve patients classified according to the 2010 ACR/EULAR criteria. Annals of the Rheumatic Diseases, 2017, 76, 341-345.	0.5	77
300	Can we use structural lesions seen on MRI of the sacroiliac joints reliably for the classification of patients according to the ASAS axial spondyloarthritis criteria? Data from the DESIR cohort. Annals of the Rheumatic Diseases, 2017, 76, 392-398.	0.5	45
301	Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis. Annals of the Rheumatic Diseases, 2017, 76, 886-890.	0.5	51
302	Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naÃ ⁻ ve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Annals of the Rheumatic Diseases, 2017, 76, 96-104.	0.5	86
303	DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open, 2017, 3, e000382.	1.8	71
304	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.5	3,366
305	Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open, 2017, 3, e000396.	1.8	99
306	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Annals of the Rheumatic Diseases, 2017, 76, 1348-1356.	0.5	36

#	Article	IF	CITATIONS
307	Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open, 2017, 3, e000397.	1.8	69
308	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. New England Journal of Medicine, 2017, 376, 652-662.	13.9	643
309	Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology, 2017, 56, 1498-1509.	0.9	78
310	Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort. RMD Open, 2017, 3, e000389.	1.8	34
311	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1550-1558.	0.5	184
312	Response to: â€~2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?' by Misra et al. Annals of the Rheumatic Diseases, 2017, 76, e48-e48.	0.5	4
313	Effects of Longâ€Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104â€Week Results From a Randomized, Placeboâ€Controlled Study. Arthritis Care and Research, 2017, 69, 1590-1598.	1.5	28
314	Response to: †The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis' by Pirilä i>et al. Annals of the Rheumatic Diseases, 2017, 76, e50-e50.	0.5	0
315	Effect of certolizumab pegol over 96â€weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open, 2017, 3, e000430.	1.8	28
316	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1102-1107.	0.5	131
317	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1101-1136.	0.5	277
318	Illness Perceptions and Outcomes in Patients with Inflammatory Bowel Disease: Is Coping a Mediator?. International Journal of Behavioral Medicine, 2017, 24, 205-214.	0.8	33
319	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Annals of the Rheumatic Diseases, 2017, 76, 88-95.	0.5	295
320	THU0352â€Tofacitinib treatment is associated with attainment of the minimally important reduction in axial mri inflammation in patients with ankylosing spondylitis. , 2017, , .		0
321	OP0168â€A phase 2a, placebo-controlled, randomized study of ABT-981, an anti-interleukin-1ALPHA and -1BETA dual variable domain immunoglobulin, to treat erosive hand osteoarthritis (EHOA). , 2017, , .		2
322	THU0386â€Use of biologics and nsaids in treating patients with axial spondyloarthritis in the us-based corrona psoriatic arthritis/spondyloarthritis (PSA/SPA) registry. , 2017, , .		0
323	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open, 2017, 3, e000445.	1.8	5
324	Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. New England Journal of Medicine, 2017, 377, 1537-1550.	13.9	434

#	Article	IF	CITATIONS
325	AB0747â€The effect of certolizumab pegol on radiographic progression over 4 years of treatment in patients with psoriatic arthritis. , 2017, , .		0
326	OP0023â€Four-year imaging outcomes in axial spondyloarthritis patients treated with certolizumab pegol, including patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. , 2017, , .		2
327	FRI0430â€Dual trajectories of disease activity and health-related quality of life in patients with ankylosing spondylitis. , 2017, , .		0
328	Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 2031-2037.	0.5	53
329	Role of erosions typical of rheumatoid arthritis in the 2010 ACR/EULAR rheumatoid arthritis classification criteria: results from a very early arthritis cohort. Annals of the Rheumatic Diseases, 2017, 76, 1911-1914.	0.5	8
330	Computer-aided evaluation of inflammatory changes over time on MRI of the spine in patients with suspected axial spondyloarthritis: a feasibility study. BMC Medical Imaging, 2017, 17, 55.	1.4	2
331	Why CAPS criteria are not diagnostic criteria?. Annals of the Rheumatic Diseases, 2017, 76, e7-e7.	0.5	6
332	SP0056â€Update of the T2T recommendations in spa. , 2017, , .		0
333	Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. Annals of the Rheumatic Diseases, 2017, 76, 1823-1828.	0.5	130
334	The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study. Arthritis Research and Therapy, 2017, 19, 96.	1.6	16
335	Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts. Arthritis Research and Therapy, 2017, 19, 118.	1.6	16
336	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 1937-1948.	2.9	32
337	The yield of a positive MRI of the spine as imaging criterion in the ASAS classification criteria for axial spondyloarthritis: results from the SPACE and DESIR cohorts. Annals of the Rheumatic Diseases, 2017, 76, 1731-1736.	0.5	42
338	Assessment of typical SpA lesions on MRI of the spine: do local readers and central readers agree in the DESIR-cohort at baseline?. Clinical Rheumatology, 2017, 36, 1551-1559.	1.0	9
339	Is the Site of Back Pain Related to the Location of Magnetic Resonance Imaging Lesions in Patients With Chronic Back Pain? Results From the Spondyloarthritis Caught Early Cohort. Arthritis Care and Research, 2017, 69, 717-723.	1.5	20
340	Early Disease Activity or Clinical Response as Predictors of Longâ€Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis. Arthritis Care and Research, 2017, 69, 1030-1039.	1.5	14
341	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Diseaseâ€Modifying Antirheumatic Drug Treatment. Arthritis and Rheumatology, 2017, 69, 506-517.	2.9	310
342	SAT0642â€Ultrasonography and intra-articular injection therapy in early rheumatoid arthritis: results		0

² from the randomised arctic trial. , 2017, , .

#	Article	IF	CITATIONS
343	SAT0675â€The role of erosions typical of rheumatoid arthritis in the 2010 acr/eular rheumatoid classification criteria: results from a very early arthritis cohort. , 2017, , .		0
344	AB0235â€Effect of baseline disease activity on achieving sustained low disease activity in baricitinib phase 3 studies. , 2017, , .		0
345	OP0216â€Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS): a randomised, placebo-controlled, phase 3 trial. , 2017, , .		3
346	OP0188â€Defining clinically important worsening based on ASDAS-CRP for axial spondyloarthritis: a data-based consensus by the assessment in spondyloarthritis international society (ASAS). , 2017, , .		0
347	FRI0087â€Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. , 2017, , .		0
348	FRI0089â€Effect of starting dose of baricitinib in achieving sustained low disease activity. , 2017, , .		0
349	OP0289â€Treat-to-target in early rheumatoid arthritis: association between sustained remission and joint damage. , 2017, , .		0
350	FRI0432â€Clinical worsening according to the patient is infrequent in axial spondyloarthritis: results of the asas-flare study in 1169 patients. , 2017, , .		0
351	OP0221â€Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixekizumab over 52 weeks. , 2017, , .		Ο
352	THU0350â€Effect of nsaid consumption on cardiovascular events in spondyloarthritis. , 2017, , .		1
353	SAT0632â€Impact of lumbar spine morphology (scoliosis) on early spondyloarthritis pattern (the) Tj ETQq1	1 0.784314	rgBT /Overloc
354	Is there a relationship between spondyloarthritis and periodontitis? A case–control study. RMD Open, 2017, 3, e000547.	1.8	5
355	FRI0151â€Disease course in seronegative ra patients classified according to the 2010 acr/eular criteria. , 2017, , .		0
356	FRIO121â€Remission at 6 months and identification of future good radiographic and physical outcome in early rheumatoid arthritis. , 2017, , .		0
357	FRI0207â€Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate, methotrexate alone or placebo: the dinora trial. , 2017, , .		Ο
358	OP0244â€Family matters: value of family history of spondyloarthritis in the diagnostic work-up of patients with chronic back pain: results from the space and desir cohorts. , 2017, , .		0
359	OP0070â€The role of individual and country-level socio-economic factors in work participation in patients with spondyloarthritis across 22 countries worldwide: results from the comospa study. , 2017, , .		0
360	THU0088â€Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study. , 2017, , .		0

#	Article	IF	CITATIONS
361	OP0223â€Abatacept in the treatment of active psoriatic arthritis: 1-year results from a phase iii study. , 2017, , .		1
362	Disease activity decrease is associated with improvement in work productivity over 1 year in early axial spondyloarthritis (SPondyloArthritis Caught Early cohort). Rheumatology, 2017, 56, 2222-2228.	0.9	18
363	Cerebral magnetic resonance imaging in quiescent Crohn's disease patients with fatigue. World Journal of Gastroenterology, 2017, 23, 1018.	1.4	12
364	Flare in axial spondyloarthritis: investigation of meaningful changes in symptomatic outcome measures. Clinical and Experimental Rheumatology, 2017, 35, 209-213.	0.4	6
365	Genetic diagnostic profiling in axial spondyloarthritis: a real world study. Clinical and Experimental Rheumatology, 2017, 35, 229-233.	0.4	16
366	Factors associated with the decision of the rheumatologist to order sacroiliac joints magnetic resonance imaging (SI-MRI) or HLA-B27 testing in the diagnostic work-up of patients with spondyloarthritis in clinical practice. Clinical and Experimental Rheumatology, 2017, 35, 122-128.	0.4	2
367	The Course of Bone Marrow Edema in Early Undifferentiated Arthritis and Rheumatoid Arthritis: A Longitudinal Magnetic Resonance Imaging Study at Bone Level. Arthritis and Rheumatology, 2016, 68, 1080-1088.	2.9	45
368	Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. Rheumatology, 2016, 55, kev340.	0.9	66
369	FRI0090â€BMI and Tender Joints Are Predictors of Not Reaching Sustained Remission in Patients Participating in An Aggressive Treat-To-Target Study: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 460.1-460.	0.5	0
370	SAT0149â€Radiographic Outcomes in Patients Achieving Clinical Remission or Low Disease Activity in A Phase 3 Study of Sarilumab plus Methotrexate in Patients with Active, Moderate-To-Severe Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 719.1-719.	0.5	0
371	FRIO433â€Factors Associated with Elevated Acute Phase Reactants in Patients with Recent Inflammatory Back Pain: Impact of C Reactive Protein on The Phenotype of Patients. Data from The Prospective Multicenter French Cohort Desir. Annals of the Rheumatic Diseases, 2016, 75, 592.2-592.	0.5	0
372	ls radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials. Arthritis Research and Therapy, 2016, 18, 212.	1.6	27
373	O49 Synovial Lymphocytic Aggregates Associate with Highly Active RA and Predict Erosive Disease Progression at 12 Months: Results from the Pathobiology of Early Arthritis Cohort. Rheumatology, 2016, , .	0.9	0
374	Effect of Comedication With Conventional Synthetic Diseaseâ€Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 2671-2679.	2.9	25
375	Are Additional Tests Needed to Rule Out Axial Spondyloarthritis in Patients Ages 16–45 Years With Shortâ€Đuration Chronic Back Pain and Maximally One Spondyloarthritis Feature?. Arthritis Care and Research, 2016, 68, 1726-1730.	1.5	6
376	SAT0375â€Certolizumab Pegol for The Treatment of Axial Spondyloarthritis: 4-Year Outcomes from The Rapid-AXSPA Trial. Annals of the Rheumatic Diseases, 2016, 75, 803.1-803.	0.5	1
377	SAT0389â€Long-Term Improvements in Workplace and Household Productivity and Social Participation over 4 Years of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. Annals of the Rheumatic Diseases. 2016. 75. 809.1-809.	0.5	0
378	Response to: â€~Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossiniet al. Annals of the Rheumatic Diseases, 2016, 75, e71-e71.	0.5	2

#	Article	IF	CITATIONS
379	Response to: â€~Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers. Annals of the Rheumatic Diseases, 2016, 75, e69-e69.	0.5	1
380	OP0227â€A Randomized Double-Blind Treatment Strategy Study Evaluating Continuation or Reduced-Frequency Dosing of Certolizumab Pegol versus Withdrawal To Maintain Low Disease Activity in Early RA Patients (C-Early Period 2). Annals of the Rheumatic Diseases, 2016, 75, 143.2-144.	0.5	1
381	Reliability of mSASSS scoring in everyday practice in DESIR-cohort study centres: cross-sectional study of agreement with trained readers. Annals of the Rheumatic Diseases, 2016, 75, 2213-2214.	0.5	6
382	Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Annals of the Rheumatic Diseases, 2016, 75, 1043-1050.	0.5	167
383	OP0002â€Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomised, Placebo-Controlled, Dose-Ranging Study. Annals of the Rheumatic Diseases, 2016, 75, 52.2-53.	0.5	5
384	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Annals of the Rheumatic Diseases, 2016, 75, 965-973.	0.5	179
385	THU0163â€Early Response as A Predictor of Long-Term Clinical Response in DMARD-NaÃ⁻ve Patients with Severe, Active and Progressive RA Treated with Certolizumab Pegol plus Optimized MTX versus Optimized MTX Alone. Annals of the Rheumatic Diseases, 2016, 75, 242.1-242.	0.5	Ο
386	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open, 2016, 2, e000221.	1.8	38
387	Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach. RMD Open, 2016, 2, e000325.	1.8	12
388	Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. Arthritis Research and Therapy, 2016, 18, 304.	1.6	30
389	The comparison of magnetic resonance imaging and radiographs to assess structural progression over 5 years in hand osteoarthritis. Rheumatology, 2016, 56, kew419.	0.9	6
390	Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Annals of the Rheumatic Diseases, 2016, 75, 1024-1033.	0.5	85
391	Synovitis and radiographic progression in non-erosive and erosive hand osteoarthritis: is erosive hand osteoarthritis a separate inflammatory phenotype?. Osteoarthritis and Cartilage, 2016, 24, 647-654.	0.6	60
392	Development and Validation of a Short Form of the Social Role Participation Questionnaire in Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2016, 43, 1386-1392.	1.0	15
393	Construct validity of the Doyle Index in the outcome domain of joint activity in hand osteoarthritis patients. Osteoarthritis and Cartilage, 2016, 24, S434.	0.6	2
394	The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2016, 43, 1680-1686.	1.0	42
395	Effect of denosumab on Japanese patients with rheumatoid arthritis: a dosea€ response study of ANG 162 (<i>D</i> enosumab) in patients with <i>R</i> heumato <i>I</i> d arthritis on methotrexate to <i>V</i> alidate inhibitory effect on bone <i>E</i> rosion (DRIVE)â€"a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Annals of the Rheumatic Diseases, 2016, 75,	0.5	157
396	Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. Rheumatology, 2016, 55, 2014-2022.	0.9	15

#	Article	IF	CITATIONS
397	Which aspects of health are most important for patients with spondyloarthritis? A Best Worst Scaling based on the ASAS Health Index. Rheumatology, 2016, 55, 1771-1776.	0.9	25
398	Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis. Arthritis Care and Research, 2016, 68, 838-844.	1.5	73
399	Rate and Predisposing Factors for Sacroiliac Joint Radiographic Progression After a Twoâ€Year Followâ€up Period in Recentâ€Onset Spondyloarthritis. Arthritis and Rheumatology, 2016, 68, 1904-1913.	2.9	63
400	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nature Reviews Rheumatology, 2016, 12, 743-750.	3.5	71
401	Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Research and Therapy, 2016, 18, 196.	1.6	192
402	THU0376â€Prevalence of Peripheral and Extra-Articular Disease in Ankylosing Spondylitis versus Non-Radiographic Axial Spondyloarthritis: A Meta-Analysis. Annals of the Rheumatic Diseases, 2016, 75, 323.2-323.	0.5	0
403	SAT0528â€Development and Validation of A Responsive Ultrasound Joint Inflammation Score for Rheumatoid Arthritis through A Data-Driven Approach. Annals of the Rheumatic Diseases, 2016, 75, 860.2-860.	0.5	Ο
404	Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ, The, 2016, 354, i4205.	3.0	200
405	THU0168â€Baricitinib Inhibits Radiographic Progression of Structural Joint Damage at 1 Year in Patients with Rheumatoid Arthritis (RA) and An Inadequate Response To csDMARDs:. Annals of the Rheumatic Diseases, 2016, 75, 244.2-245.	0.5	0
406	THU0165â€Long-Term Radiographic and Patient-Reported Outcomes Based on Clinical Disease Activity Index Responses with Tofacitinib at 6 Months. Annals of the Rheumatic Diseases, 2016, 75, 243.1-243.	0.5	0
407	THU0073â€DAS28-CRP and DAS28-ESR Cutoffs for High Disease Activity in Rheumatoid Arthritis Are Not Interchangeable: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 205.1-205.	0.5	0
408	OP0119â€Predictors of Radiographic Progression in Early Rheumatoid Arthritis Patients Treated by An Aggressive Tight Control Regime: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 100.2-100.	0.5	0
409	OP0084â€Validation of The Asas Health Index: Results of A Multicenter International Study in 23 Countries: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 86.2-86.	0.5	0
410	THU0157â€Clinical Outcomes at Week 104 and Analysis of Associated Baseline Factors after An Initial 1 Year of Certolizumab Pegol and MTX Treatment in MTX-NaÃ⁻ve Patients with Early RA: Results from The Second Year of The C-Opera Study. Annals of the Rheumatic Diseases, 2016, 75, 239.1-239.	0.5	0
411	SAT0405â€No Radiological Sacroiliac Joint Progression after 2 Years of Etanercept Treatment in Non-Radiographic Axial Spondyloarthritis: Data from The Embark Study. Annals of the Rheumatic Diseases, 2016, 75, 816.2-816.	0.5	1
412	SAT0388â€Long-Term Efficacy and Tolerability of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results of The Open-Label Extension of A Randomized, Double-Blind Study. Annals of the Rheumatic Diseases, 2016, 75, 808.2-809.	0.5	0
413	SAT0399â€Efficacy of Golimumab for Nonradiographic Axial Spondyloarthritis: Subgroup Analysis by Baseline MRI and C-Reactive Protein Status: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 813.3-814.	0.5	0
414	SAT0160â€Clinical and Radiographic Outcomes after 2 Years of Sarilumab in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 724.1-724.	0.5	2

#	Article	IF	CITATIONS
415	Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?. RMD Open, 2016, 2, e000283.	1.8	26
416	Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity. RMD Open, 2016, 2, e000177.	1.8	7
417	SAT0058â€Consistency of Radiographic Responses with Sarilumab plus Methotrexate across Subpopulations of Patients with Rheumatoid Arthritis in A Phase 3 Study. Annals of the Rheumatic Diseases, 2016, 75, 685.1-685.	0.5	2
418	What is the reliability of non-trained investigators in recognising structural MRI lesions of sacroiliac joints in patients with recent inflammatory back pain? Results of the DESIR cohort. RMD Open, 2016, 2, e000303.	1.8	14
419	Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages. RMD Open, 2016, 2, e000311.	1.8	31
420	Work Outcome in Patients With Ankylosing Spondylitis: Results From a 12‥ear Followup of an International Study. Arthritis Care and Research, 2016, 68, 544-552.	1.5	35
421	Are conventional radiographs still of value?. Current Opinion in Rheumatology, 2016, 28, 310-315.	2.0	3
422	Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis. Rheumatology, 2016, 55, 1295-1300.	0.9	8
423	DAS steered therapy in clinical practice; cross-sectional results from the METEOR database. BMC Musculoskeletal Disorders, 2016, 17, 33.	0.8	2
424	Social Role Participation in Patients With Ankylosing Spondylitis: A Crossâ€Sectional Comparison With Population Controls. Arthritis Care and Research, 2016, 68, 1899-1905.	1.5	15
425	Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1914-1921.	2.9	64
426	Digital ulcers predict a worse disease course in patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 681-686.	0.5	111
427	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Annals of the Rheumatic Diseases, 2016, 75, 16-22.	0.5	275
428	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, 75, 3-15.	0.5	1,114
429	Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis. Clinical Rheumatology, 2016, 35, 1759-1767.	1.0	22
430	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2016, 75, 1958-1963.	0.5	383
431	ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. Rheumatology, 2016, 55, 80-88.	0.9	52
432	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placeboâ€Controlled Study. Arthritis Care and Research, 2016, 68, 267-274.	1.5	69

#	Article	IF	CITATIONS
433	Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Preâ€6pecified Analysis of Two Phase III Trials. Arthritis Care and Research, 2016, 68, 299-307.	1.5	6
434	Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. Rheumatology, 2016, 55, 1217-1224.	0.9	31
435	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. Annals of the Rheumatic Diseases, 2016, 75, 1034-1042.	0.5	53
436	Classifying Back Pain and Peripheral Joint Complaints in Inflammatory Bowel Disease Patients: A Prospective Longitudinal Follow-up Study. Journal of Crohn's and Colitis, 2016, 10, 166-175.	0.6	48
437	Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. Journal of Rheumatology, 2016, 43, 607-617.	1.0	32
438	Preliminary definitions of â€~flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. Annals of the Rheumatic Diseases, 2016, 75, 991-996.	0.5	48
439	Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?. Annals of the Rheumatic Diseases, 2016, 75, 1262-1263.	0.5	24
440	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 2016, 75, 490-498.	0.5	98
441	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 2016, 75, 499-510.	0.5	743
442	Signal intensity loss of the intervertebral discs in the cervical spine of young patients on fluid sensitive sequences. Skeletal Radiology, 2016, 45, 375-381.	1.2	11
443	MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2016, 75, 1486-1493.	0.5	103
444	Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Annals of the Rheumatic Diseases, 2016, 75, 1328-1335.	0.5	81
445	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Annals of the Rheumatic Diseases, 2016, 75, 75-83.	0.5	94
446	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2016, 75, 1016-1023.	0.5	188
447	Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. Annals of the Rheumatic Diseases, 2016, 75, 874-878.	0.5	49
448	Prevalence of degenerative changes of the spine on magnetic resonance images and radiographs in patients aged 16–45 years with chronic back pain of short duration in the Spondyloarthritis Caught Early (SPACE) cohort. Rheumatology, 2016, 55, 56-65.	0.9	45
449	Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?. Annals of the Rheumatic Diseases, 2016, 75, 1308-1314.	0.5	84
450	First step in the development of an ultrasound joint inflammation score for rheumatoid arthritis using a data-driven approach. Annals of the Rheumatic Diseases, 2016, 75, 1444-1451.	0.5	13

#	Article	IF	CITATIONS
451	MRI findings predict radiographic progression and development of erosions in hand osteoarthritis. Annals of the Rheumatic Diseases, 2016, 75, 117-123.	0.5	64
452	Increasing synovitis and bone marrow lesions are associated with incident joint tenderness in hand osteoarthritis. Annals of the Rheumatic Diseases, 2016, 75, 702-708.	0.5	40
453	Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials. RMD Open, 2016, 2, e000219.	1.8	8
454	Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS. Clinical and Experimental Rheumatology, 2016, 34, 214-21.	0.4	10
455	Automated joint space width quantification of hand and wrist joints: a proof of concept study. Clinical and Experimental Rheumatology, 2016, 34, S34-S39.	0.4	17
456	A Randomized, Doubleâ€Blind, Placeboâ€Controlled, Sixteenâ€Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2015, 67, 2702-2712.	2.9	174
457	THU0425â€Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2). Annals of the Rheumatic Diseases, 2015, 74, 352.3-353.	0.5	1
458	SAT0238â€Gender-Attributable Differences in Outcome of Ankylosing Spondylitis: Long-Term Results from the Outcome in Ankylosing Spondylitis International Study. Annals of the Rheumatic Diseases, 2015, 74, 744.2-745.	0.5	0
459	SAT0185â€Clinical and Radiographic Efficacy of Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-NaÃ⁻ve Patients with Rheumatoid Arthritis in a Phase 3, Randomized, Double-Blind, Placebo-Controlled International Study. Annals of the Rheumatic Diseases, 2015, 74, 722.1-722.	0.5	0
460	SAT0222â€Effects of Tofacitinib on MRI Endpoints in Methotrexate-Naive Early Rheumatoid Arthritis: A Phase 2 MRI Study with Semi-Quantitative and Quantitative Endpoints. Annals of the Rheumatic Diseases, 2015, 74, 738-738.	0.5	4
461	THUO414â€Secukinumab Inhibits Radiographic Progression in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 1). Annals of the Rheumatic Diseases, 2015, 74, 347.2-348.	0.5	2
462	AB1135â€Preliminary Definitions of "Flare―in Axial Spondyloarthritis, Based on Pain, Basdai and ASDAS-CRP: An Asas Initiative. Annals of the Rheumatic Diseases, 2015, 74, 1281.2-1281.	0.5	0
463	Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open, 2015, 1, e000153.	1.8	85
464	SAT0164â€The First Study of Certolizumab Pegol in Combination with Methotrexate in Dmard-NaÃ⁻ve Early Rheumatoid Arthritis Patients Led to Sustained Clinical Response and Inhibition of Radiographic Progression at 52 Weeks: The C-Early Randomized, Double-Blind, Controlled Phase 3 Study. Annals of the Rheumatic Diseases, 2015, 74, 712.1-712.	0.5	1
465	THU0202â€Clinical Responses and Improvements in Patient-reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol. Annals of the Rheumatic Diseases, 2015, 74, 268.2-269.	0.5	1
466	SAT0173â€Baseline Parameters Identified in Early, Methotrexate-NaÃ⁻ve Rheumatoid Arthritis Patients with Better Outcomes with Certolizumab Pegol+Methotrexate Compared to Placebo+Methotrexate: Post-Hoc Analyses of C-OPERA, A Randomized, Controlled, Phase 3 Study. Annals of the Rheumatic Diseases, 2015, 74, 716.2-717.	0.5	8
467	SAT0619â€Ultrasonography Versus Clinical Examination in Early Dmard-NaÃ⁻ve Rheumatoid Arthritis – a Comparative Study on the Individual Joint Level: Table 1 Annals of the Rheumatic Diseases, 2015, 74, 885.2-885.	0.5	0
468	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?. RMD Open, 2015, 1, e000155-e000155.	1.8	34

#	Article	IF	CITATIONS
469	THU0238â€A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Subcutaneous Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 2015, 74, 283.1-283.	0.5	2
470	Computerised versus conventional methodology of radiographic joint destruction assessment in early rheumatoid arthritis. RMD Open, 2015, 1, e000148.	1.8	2
471	SAT0564â€Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol. Annals of the Rheumatic Diseases, 2015, 74, 864.2-865.	0.5	0
472	Studies on ageing and the severity of radiographic joint damage in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 222.	1.6	21
473	Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 133.	1.6	17
474	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Research and Therapy, 2015, 17, 245.	1.6	22
475	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Research and Therapy, 2015, 17, 325.	1.6	16
476	Development of Multinational Definitions of Minimal Clinically Important Improvement and Patient Acceptable Symptomatic State in Osteoarthritis. Arthritis Care and Research, 2015, 67, 972-980.	1.5	82
477	THU0201â€Factors Associated with Structural Damage in the Spine, as Measured by X-ray, in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol Over 96 Weeks. Annals of the Rheumatic Diseases, 2015, 74, 268.1-268.	0.5	2
478	FRI0356â€Studies on Ageing and the Severity of Radiographic Joint Damage in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 554.3-555.	0.5	1
479	FRI0234â€Spinal Radiographic Progression in Early Axial Spondyloarthritis: Data from the Desir Cohort. Annals of the Rheumatic Diseases, 2015, 74, 509.2-509.	0.5	0
480	FRI0066â€The Clinical and Ultrasonographic Presentation of Seronegative RA is More Severe Compared to Seropositive RA in an Inception Cohort of Dmard-NaÃ⊤ve Patients Classified According to the 2010 ACR/Eular Criteria:. Annals of the Rheumatic Diseases, 2015, 74, 443.2-443.	0.5	0
481	SAT0220â€Radiographic Progression in Modern RA Trials is Still a Robust Outcome: Results of Comprehensive Sensitivity Analysis in Two Phase 3 Trials with Tofacitinib. Annals of the Rheumatic Diseases, 2015, 74, 737.2-737.	0.5	0
482	OP0041â€MRI Inflammation and Fat Deposition Both Contribute to Syndesmophyte Formation at the Same Site: A Multi-Level Analysis in Patients with Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2015, 74, 81.2-82.	0.5	0
483	AB1158â€Quality of Life in Patients with Active Peripheral SPA is Similarly Impaired as in Other Rheumatic Diseases and Influenced by Disease Activity But not Disease Duration. Annals of the Rheumatic Diseases, 2015, 74, 1290.1-1290.	0.5	0
484	Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve‥ear Data. Arthritis Care and Research, 2015, 67, 1571-1577.	1.5	16
485	Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis) Tj ETQq1 1 0.	784314 rg 1.5	gBT_/Overloc 64
486	Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life	11	20

1.1 32

⁴⁸⁶ Outcomes in the Canadian Early Arthritis Cohort (CATCH). PLoS ONE, 2015, 10, e0135327.

#	Article	IF	CITATIONS
487	Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. Rheumatology, 2015, 54, 994-1007.	0.9	51
488	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis and Rheumatology, 2015, 67, 1424-1437.	2.9	213
489	Concordance between inflammation at physical examination and on MRI in patients with early arthritis. Annals of the Rheumatic Diseases, 2015, 74, 506-512.	0.5	52
490	High Degree of Nonadherence to Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 386-390.	1.0	18
491	Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls. Journal of Rheumatology, 2015, 42, 2369-2375.	1.0	25
492	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Annals of the Rheumatic Diseases, 2015, 74, 8-13.	0.5	223
493	Sponyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort. Arthritis Research and Therapy, 2015, 17, 265.	1.6	6
494	Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. RMD Open, 2015, 1, e000128.	1.8	17
495	Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology, 2015, 54, 633-640.	0.9	57
496	Disease Activity in Ankylosing Spondylitis and Associations to Markers of Vascular Pathology and Traditional Cardiovascular Disease Risk Factors: A Cross-sectional Study. Journal of Rheumatology, 2015, 42, 645-653.	1.0	33
497	Effect of Certolizumab Pegol Over Ninety‣ix Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial. Arthritis and Rheumatology, 2015, 67, 668-677.	2.9	49
498	Golimumab administered subcutaneously every 4â€weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Annals of the Rheumatic Diseases, 2015, 74, 757-761.	0.5	92
499	The burden of non-radiographic axial spondyloarthritis. Seminars in Arthritis and Rheumatism, 2015, 44, 556-562.	1.6	112
500	Analysis of Integrated Radiographic Data From Two Longâ€Term, Open‣abel Extension Studies of Adalimumab for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 180-186.	1.5	13
501	Aiming for a simpler early arthritis MRI protocol: can Gd contrast administration be eliminated?. European Radiology, 2015, 25, 1520-1527.	2.3	42
502	Reference intervals of spinal mobility measures in normal individuals: the mobility study. Annals of the Rheumatic Diseases, 2015, 74, 1218-1224.	0.5	45
503	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2015, 386, 1137-1146.	6.3	722
504	Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Rheumatology, 2015, 54, 1210-1219.	0.9	40

#	Article	IF	CITATIONS
505	14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 1587-1594.	1.0	28
506	Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Annals of the Rheumatic Diseases, 2015, 74, 1483-1487.	0.5	99
507	Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. Joint Bone Spine, 2015, 82, 345-351.	0.8	92
508	Magnetic Resonance Imaging in Hand Osteoarthritis: Intraobserver Reliability and Criterion Validity for Clinical and Structural Characteristics. Journal of Rheumatology, 2015, 42, 1224-1230.	1.0	23
509	Metric Properties of the SPARCC Score of the Sacroiliac Joints — Data from Baseline, 3-month, and 12-month Followup in the SPACE Cohort. Journal of Rheumatology, 2015, 42, 1186-1193.	1.0	23
510	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. Annals of the Rheumatic Diseases, 2015, 74, 1567-1570.	0.5	31
511	Brief Report: Calculating the Ankylosing Spondylitis Disease Activity Score If the Conventional Câ€Reactive Protein Level Is Below the Limit of Detection or If Highâ€Sensitivity Câ€Reactive Protein Is Used: An Analysis in the DESIR Cohort. Arthritis and Rheumatology, 2015, 67, 408-413.	2.9	50
512	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Annals of the Rheumatic Diseases, 2015, 74, 963-969.	0.5	36
513	Classification of axial SpA based on positive imaging (radiographs and/or MRI of the sacroiliac joints) by local rheumatologists or radiologists versus central trained readers in the DESIR cohort. Annals of the Rheumatic Diseases, 2015, 74, 2016-2021.	0.5	65
514	IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. Rheumatology, 2015, 54, 728-735.	0.9	48
515	CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up. Annals of the Rheumatic Diseases, 2015, 74, 1562-1566.	0.5	31
516	EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Annals of the Rheumatic Diseases, 2015, 74, 1327-1339.	0.5	402
517	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. New England Journal of Medicine, 2015, 373, 1329-1339.	13.9	629
518	Effect of certolizumab pegol over 96â€weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open, 2015, 1, e000119.	1.8	40
519	Instruments Measuring Pain, Physical Function, or Patient's Global Assessment in Hand Osteoarthritis: A Systematic Literature Search. Journal of Rheumatology, 2015, 42, 2118-2134.	1.0	47
520	LB0001â€Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study:. Annals of the Rheumatic Diseases, 2015, 74, 79.2-79.	0.5	12
521	Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. Journal of Rheumatology, 2015, 42, 2190-2197.	1.0	62
522	Quality indicators in rheumatoid arthritis: results from the METEOR database. Rheumatology, 2015, 54, 1630-1639.	0.9	23

#	ARTICLE	IF	CITATIONS
523	Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24â€weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Annals of the Rheumatic Diseases, 2015, 74, 44-51.	0.5	30
524	Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis. Journal of Rheumatology, 2015, 42, 2361-2368.	1.0	3
525	Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. Rheumatology, 2015, 54, 83-90.	0.9	28
526	Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort. Annals of the Rheumatic Diseases, 2015, 74, 746-751.	0.5	60
527	Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Annals of the Rheumatic Diseases, 2015, 74, 830-835.	0.5	161
528	Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Annals of the Rheumatic Diseases, 2015, 74, 52-59.	0.5	174
529	How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?. Annals of the Rheumatic Diseases, 2015, 74, 1132-1137.	0.5	95
530	Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: †Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?' by van Hoeven <i>et al</i> . Annals of the Rheumatic Diseases, 2015, 74, 1-1.	0.5	3
531	Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort. PLoS ONE, 2015, 10, e0134974.	1.1	26
532	SAT0099â€Preferences of Patients with Spondyloarthritis for the Items of the ASAS Health Index: A Best Worst Scaling: Table 1 Annals of the Rheumatic Diseases, 2014, 73, 626.1-626.	0.5	1
533	SAT0210â€X-Ray and MRI Results from A Phase lib Study of Subcutaneous Anti-Interleukin-6 Monoclonal Antibody Clazakizumab with or without MTX in Adults with Moderate-To-Severe Active RA and Inadequate Response to Conventional DMARDS Including Methotrexate. Annals of the Rheumatic Diseases, 2014, 73, 665.3-666.	0.5	0
534	FRI0222â€Translation and Cross-Cultural Adaptation of the ASAS Health Index and the Environmental Item Set into 15 Languages. Annals of the Rheumatic Diseases, 2014, 73, 463.1-463.	0.5	2
535	FRI0278â€The First Early Rheumatoid Arthritis, Certolizumab Pegol, Multicenter, Double-Blind, Randomized, Parallel-Group Study: C-Opera, in Patients Fulfilling the 2010 Acr/Eular Classification Criteria, Demonstrates Inhibition of Joint Damage Progression. Annals of the Rheumatic Diseases, 2014, 73, 484.1-484.	0.5	3
536	Treatment Target and Followup Measures for Patients with Gout: A Systematic Literature Review. Journal of rheumatology Supplement, The, 2014, 92, 55-62.	2.2	7
537	Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial. Modern Rheumatology, 2014, 24, 552-560.	0.9	40
538	Introduction: Diagnosis and Management of Gout. Systematic Literature Reviews of the 3e Initiative 2011-2012. Journal of rheumatology Supplement, The, 2014, 92, 1-2.	2.2	2
539	Updating the OMERACT Filter: Discrimination and Feasibility. Journal of Rheumatology, 2014, 41, 1005-1010.	1.0	18
540	SAT0355â€Observed Incidence Rates of Uveitis following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 721.3-722.	0.5	0

#	Article	IF	CITATIONS
541	The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4â€years of the GO-RAISE trial. Annals of the Rheumatic Diseases, 2014, 73, 1107-1113.	0.5	105
542	Clinical efficacy, radiographic and safety findings through 5â€years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Annals of the Rheumatic Diseases, 2014, 73, 1689-1694.	0.5	112
543	Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study. BMJ Open, 2014, 4, e005246-e005246.	0.8	18
544	Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Annals of the Rheumatic Diseases, 2014, 73, 233-237.	0.5	70
545	MRI-detected subclinical joint inflammation is associated with radiographic progression. Annals of the Rheumatic Diseases, 2014, 73, 2034-2037.	0.5	31
546	Neutral lateral fingertip-to-floor distance can be derived from height. Annals of the Rheumatic Diseases, 2014, 73, 1748-1749.	0.5	2
547	Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Annals of the Rheumatic Diseases, 2014, 73, 1819-1825.	0.5	161
548	Agreement Between Clinical Practice and Trained Central Reading in Reading of Sacroiliac Joints on Plain Pelvic Radiographs: Results From the DESIR Cohort. Arthritis and Rheumatology, 2014, 66, 2403-2411.	2.9	130
549	When to Adjust Therapy in Patients with Rheumatoid Arthritis After Initiation of Etanercept plus Methotrexate or Methotrexate Alone: Findings from a Randomized Study (COMET). Journal of Rheumatology, 2014, 41, 1922-1934.	1.0	8
550	Comment on: â€~Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial' by Qian-wen <i>et al</i> . Annals of the Rheumatic Diseases, 2014, 73, e62-e62.	0.5	13
551	Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis. Scandinavian Journal of Rheumatology, 2014, 43, 49-53.	0.6	26
552	Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of "Truth― Content, Face, and Construct Validity. Journal of Rheumatology, 2014, 41, 1000-1004.	1.0	34
553	Are Rheumatoid Arthritis Patients Discernible from Other Early Arthritis Patients Using 1.5T Extremity Magnetic Resonance Imaging? A Large Cross-sectional Study. Journal of Rheumatology, 2014, 41, 1630-1637.	1.0	23
554	Assessment of sacroiliitis by radiographs and MRI. Current Opinion in Rheumatology, 2014, 26, 384-388.	2.0	20
555	Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Modern Rheumatology, 2014, 24, 715-724.	0.9	49
556	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 1755-1760.	0.5	11
557	The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial. Journal of Rheumatology, 2014, 41, 1095-1103.	1.0	41
558	Referral Patterns, Diagnosis, and Disease Management of Patients With Axial Spondyloarthritis. Journal of Clinical Rheumatology, 2014, 20, 411-417.	0.5	24

#	Article	IF	CITATIONS
559	Proposal for a new nomenclature of disease-modifying antirheumatic drugs: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 3-5.	0.5	212
560	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 529-535.	0.5	456
561	Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2014, 66, 667-673.	2.9	65
562	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Annals of the Rheumatic Diseases, 2014, 73, 349-356.	0.5	308
563	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist. Journal of Rheumatology, 2014, 41, 2120-2128.	1.0	57
564	Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 2104-2113.	1.0	72
565	Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Annals of the Rheumatic Diseases, 2014, 73, 2094-2100.	0.5	45
566	Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Annals of the Rheumatic Diseases, 2014, 73, 39-47.	0.5	378
567	Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitis. Rheumatology, 2014, 53, 1054-1064.	0.9	29
568	Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 238-242.	0.5	65
569	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Annals of the Rheumatic Diseases, 2014, 73, 86-94.	0.5	256
570	Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Annals of the Rheumatic Diseases, 2014, 73, 48-55.	0.5	393
571	Aiming for a shorter rheumatoid arthritis MRI protocol: can contrast-enhanced MRI replace T2 for the detection of bone marrow oedema?. European Radiology, 2014, 24, 2614-2622.	2.3	34
572	Lifestyle Interventions for the Treatment of Gout: A Summary of 2 Cochrane Systematic Reviews. Journal of rheumatology Supplement, The, 2014, 92, 26-32.	2.2	20
573	Urate-Lowering Therapy for the Management of Gout: A Summary of 2 Cochrane Reviews. Journal of rheumatology Supplement, The, 2014, 92, 33-41.	2.2	11
574	Preventing Attacks of Acute Gout When Introducing Urate-Lowering Therapy: A Systematic Literature Review. Journal of rheumatology Supplement, The, 2014, 92, 42-47.	2.2	14
575	Treatment of Gout Patients with Impairment of Renal Function: A Systematic Literature Review. Journal of rheumatology Supplement, The, 2014, 92, 48-54.	2.2	13
576	Treatment of Asymptomatic Hyperuricemia for the Prevention of Gouty Arthritis, Renal Disease, and Cardiovascular Events: A Systematic Literature Review. Journal of rheumatology Supplement, The, 2014, 92, 70-74.	2.2	23

#	Article	IF	CITATIONS
577	ls HLA-B27 Increased in Patients Diagnosed with Undifferentiated Arthritis? Results from the Leiden Early Arthritis Cohort. Journal of Rheumatology, 2014, 41, 1948-1951.	1.0	1
578	Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2014, 66, 2091-2102.	2.9	185
579	Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC) revisited. Annals of the Rheumatic Diseases, 2014, 73, 1067-1070.	0.5	15
580	Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Annals of the Rheumatic Diseases, 2014, 73, 1455-1461.	0.5	263
581	The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Annals of the Rheumatic Diseases, 2014, 73, 132-137.	0.5	158
582	How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review. Clinical Rheumatology, 2014, 33, 1313-1322.	1.0	41
583	Bone Marrow Edema on Magnetic Resonance Imaging (MRI) of the Sacroiliac Joints Is Associated with Development of Fatty Lesions on MRI over a 1-year Interval in Patients with Early Inflammatory Low Back Pain: A 2-year Followup Study. Journal of Rheumatology, 2014, 41, 1088-1094.	1.0	8
584	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases, 2014, 73, 492-509.	0.5	1,688
585	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. Arthritis and Rheumatology, 2014, 66, 2649-2656.	2.9	81
586	Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. Annals of the Rheumatic Diseases, 2014, 73, 391-395.	0.5	38
587	Interventions for Tophi in Gout: A Cochrane Systematic Literature Review. Journal of rheumatology Supplement, The, 2014, 92, 63-69.	2.2	11
588	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2014, 73, 6-16.	0.5	397
589	Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: A cross-sectional study. Seminars in Arthritis and Rheumatism, 2014, 44, 309-313.	1.6	18
590	SAT0351â€Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Outcomes of the Rapid-Axspa Trial. Annals of the Rheumatic Diseases, 2014, 73, 719.3-720.	0.5	0
591	SAT0337â€Clinical Response and Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Three Years of Adalimumab Therapy: Table 1 Annals of the Rheumatic Diseases, 2014, 73, 714.1-714.	0.5	1
592	FRI0326â€Efficacy and Safety of Tabalumab, an Anti-B Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis Who HAD an Inadequate Response to Methotrexate Therapy: Results from A Phase 3 Multicenter, Randomized, Double-Blind Study. Annals of the Rheumatic Diseases, 2014, 73, 504.2-504.	0.5	0
593	86. Head-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in Rheumatoid Arthritis: Blinded Two-Year Results from the Ample Study. Rheumatology, 2014, 53, i88-i88.	0.9	0
594	SAT0372â€Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 48-Week Treatment Data: Table 1 Annals of the Rheumatic Diseases, 2014, 73, 728.1-728.	0.5	1

#	Article	IF	CITATIONS
505	FRIOO19â€Clinical Responses by Baseline RA Disease Duration in the AMPLE (Abatacept Versus Adalimumab) 1	-	
595	of the Rheumatic Diseases, 2014, 73, 387.3-388.	0.5	1
596	SAT0338â€Disease Activity and Clinical Response Early in the Course of Treatment PREDICT Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol. Annals of the Rheumatic Diseases, 2014, 73, 714.2-715.	0.5	0
597	OP0070â€Inequity: Level of Education is Associated with Access to Biologic DMARDS Even in A Country with Highly Developed Social Welfare (NORWAY):. Annals of the Rheumatic Diseases, 2014, 73, 87.1-87.	0.5	1
598	SAT0339â€Asas40 and ASDAS Responses Are Associated with Improved Physical Function, Hrqol, and Work Productivity in Patients with Non-Radiographic Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 715.1-715.	0.5	0
599	The ASAS Health Index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis. Clinical and Experimental Rheumatology, 2014, 32, S-105-8.	0.4	17
600	Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?. Arthritis Research and Therapy, 2013, 15, R14.	1.6	48
601	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2013, 382, 1705-1713.	6.3	518
602	Magnetic resonance imaging of the sacroiliac joints in the early detection of spondyloarthritis: no added value of gadolinium compared with short tau inversion recovery sequence. Rheumatology, 2013, 52, 1220-1224.	0.9	83
603	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 804-814.	0.5	504
604	Tofacitinib (CPâ€690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelveâ€month data from a twentyâ€four–month phase III randomized radiographic study. Arthritis and Rheumatism, 2013, 65, 559-570.	6.7	481
605	Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). Rheumatology, 2013, 52, 321-325.	0.9	28
606	Headâ€ŧoâ€head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis and Rheumatism, 2013, 65, 28-38.	6.7	225
607	Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Annals of the Rheumatic Diseases, 2013, 72, 815-822.	0.5	449
608	Cross-sectional and longitudinal associations between radiographic features and measures of pain and physical function in hand osteoarthritis. Osteoarthritis and Cartilage, 2013, 21, 1191-1198.	0.6	67
609	Review: Nonradiographic axial spondyloarthritis: New definition of an old disease?. Arthritis and Rheumatism, 2013, 65, 543-551.	6.7	153
610	ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. Annals of the Rheumatic Diseases, 2013, 72, 1646-1653.	0.5	127
611	Tumor Necrosis Factor α Inhibition in Radiographic and Nonradiographic Axial Spondyloarthritis: Results From a Large Observational Cohort. Arthritis and Rheumatism, 2013, 65, 3096-3106.	6.7	129
612	Clinical efficacy, radiographic and safety findings through 2â€years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Annals of the Rheumatic Diseases, 2013, 72, 1777-1785.	0.5	77

#	Article	IF	CITATIONS
613	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.5	102
614	FRIO425â€Similar levels of disease activity in patients with oligoarticular vs. polyarticular peripheral spondyloarthritis. Annals of the Rheumatic Diseases, 2013, 72, A518.2-A518.	0.5	0
615	SAT0261â€Which Conventional DMARD to Select in the Treatment of Psoriatic Arthritis (PSA)? Data From Nor-Dmard on 1351 Treatment Courses with Methotrexate (MTX), Sulfasalazine (SSZ) And Leflunomide (LEF). Annals of the Rheumatic Diseases, 2013, 72, A670.2-A671.	0.5	0
616	The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Annals of the Rheumatic Diseases, 2013, 72, 665-671.	0.5	110
617	Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort. Rheumatology, 2013, 52, 1492-1499.	0.9	151
618	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Annals of the Rheumatic Diseases, 2013, 72, 479-481.	0.5	114
619	Performances of the Assessment of SpondyloArthritis International Society Axial Spondyloarthritis Criteria for Diagnostic and Classification Purposes in Patients Visiting a Rheumatologist Because of Chronic Back Pain: Results From a Multicenter, Crossâ€Sectional Study. Arthritis Care and Research, 2013. 65. 1472-1481.	1.5	35
620	From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials. Annals of the Rheumatic Diseases, 2013, 72, 1113-1117.	0.5	24
621	SAT0276â€Improvements in Productivity at Paid Work and Within Household, and Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol in Patients with Psoriatic Arthritis: Results of Rapid-PSA Study. Annals of the Rheumatic Diseases, 2013, 72, A676.2-A676.	0.5	0
622	SAT0473â€Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the rheumatoid arthritis impact of disease (RAID). Annals of the Rheumatic Diseases, 2013, 71, 632.3-632.	0.5	0
623	AB1065â€Diagnosing gout without joint fluid aspiration: A systematic literature review using monosodium urate crystals as a reference standard. Annals of the Rheumatic Diseases, 2013, 71, 699.4-699.	0.5	0
624	AB0908â€Spinal mobility measures are dependent on age – the mobility study:. Annals of the Rheumatic Diseases, 2013, 71, 690.14-690.	0.5	0
625	FRIO432â€Comparison of tests for lumbar flexion and hip function in patients with axial spondyloarthritis and in healthy controls. Annals of the Rheumatic Diseases, 2013, 72, A521.1-A521.	0.5	0
626	FRIO438â€Disease management of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients is similar in academic and community practice among 654 surveyed rheumatologists. Annals of the Rheumatic Diseases, 2013, 72, A523.1-A523.	0.5	0
627	SAT0280â€Intermalleolar distance and internal hip rotation are dependent on height – the mobility study. Annals of the Rheumatic Diseases, 2013, 71, 566.3-567.	0.5	0
628	FRIO440â€Referral patterns and diagnosis of patients with axial spondyloarthritis: results of an international survey. Annals of the Rheumatic Diseases, 2013, 72, A524.1-A524.	0.5	0
629	SAT0281â€Impact of Imputation Methodology on Radiographic Progression Outcomes in the Rapid-Psa Study Of Certolizumab Pegol In Patients With Psoriatic Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A678.2-A678.	0.5	0
630	OP0106â€Effect of Certolizumab Pegol on Signs and Symptoms of Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24-Week Results of Rapid-Axspa Study. Annals of the Rheumatic Diseases, 2013, 72, A86.2-A87.	0.5	4

Désirée M Van Der Heijde

#	Article	IF	CITATIONS
631	THU0209â€Disease Activity and Structural Damage-Related Differences in Functional Disability in Early and Established Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A235.1-A235.	0.5	0
632	THU0013â€Interaction between two common HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis. Annals of the Rheumatic Diseases, 2013, 71, 158.1-158.	0.5	1
633	FRI0294â€Feasibility of radiographic damage scores in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2013, 71, 413.3-413.	0.5	0
634	OP0266â€Disease burden is comparable in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: Implications for treatment:. Annals of the Rheumatic Diseases, 2013, 71, 146.2-146.	0.5	0
635	SAT0470â€Unblinding the sequence when reading radiographs in rheumatoid arthritis increases efficiency and does not lead to bias:. Annals of the Rheumatic Diseases, 2013, 71, 631.2-631.	0.5	0
636	THU0278â€The effect of anti-tumor necrosis factor therapy with golimumab on radiographic progression in definite ankylosing spondylitis: 4-year results:. Annals of the Rheumatic Diseases, 2013, 71, 249.2-249.	0.5	2
637	SAT0005â€RA genetic susceptibility loci are associated with baseline radiographic joint damage in early RA. Annals of the Rheumatic Diseases, 2013, 71, 472.2-472.	0.5	0
638	AB0883â€Evaluating patient-reported outcomes in patients with early spondyloarthritis in the desir cohort:. Annals of the Rheumatic Diseases, 2013, 71, 689.6-689.	0.5	0
639	FRIO439â€High economic burden of axial spondyloarthritis related to paid work and household productivity at baseline in the rapid-axspa study: differences and similarities between ankylosing spondylitis and non-radiographic axial spondyloarthritis. Annals of the Rheumatic Diseases, 2013, 72, A523.2-A524.	0.5	3
640	SAT0127â€Effective disease control following up to 10 years of treatment with adalimumab in patients with long-standing rheumatoid arthritis and an inadequate response to methotrexate: final 10-year results of the DE019 trial. Annals of the Rheumatic Diseases, 2013, 71, 513.2-513.	0.5	1
641	AB0275â€14-3-3 eta is an independent marker of joint damage that complements CRP and anti-CCP:. Annals of the Rheumatic Diseases, 2013, 71, 653.8-653.	0.5	0
642	OP0107â€Improvements in Work and Household Productivity after 24 Weeks of Certolizumab Pegol in Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of Rapid-Axspa Study. Annals of the Rheumatic Diseases, 2013, 72, A87.1-A87.	0.5	1
643	OP0022â€Abatacept sc versus adalimumab on background methotrexate in RA: One year results from the ample study. Annals of the Rheumatic Diseases, 2013, 71, 60.1-60.	0.5	11
644	FRIO420â€Long term inhibition of IL-17a with secukinumab reduces spinal inflammation but has no influence on fatty lesions as assessed by magnetic resonance imaging in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2013, 72, A516.1-A516.	0.5	0
645	THU0275â€Sustained efficacy of adalimumab in patients with non-radiographic axial spondyloarthritis: Week 68 results from ability 1:. Annals of the Rheumatic Diseases, 2013, 71, 248.1-248.	0.5	9
646	FRIO419â€Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12-week magnetic resonance imaging results of rapid-axspa study. Annals of the Rheumatic Diseases, 2013, 72, A515.2-A516.	0.5	3
647	AB1066â€Quality of life and disability assessment in gout: A systematic literature review. Annals of the Rheumatic Diseases, 2013, 71, 699.5-699.	0.5	0
648	AB0459â€Analysis of integrated radiographic data for two long-term, open-label extension studies of adalimumab. Annals of the Rheumatic Diseases, 2013, 71, 663.15-663.	0.5	0

#	Article	IF	CITATIONS
649	FRI0393â€Predictive value of history of digital ulcers in a eustar cohort of patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, A506.1-A506.	0.5	0
650	AB0543â€Factors associated with work disability in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2013, 72, A955.2-A955.	0.5	0
651	THU0190â€Long-Term Impact of Delaying Combination Therapy with Adalimumab Plus Methotrexate by 2 Years in Patients with Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial. Annals of the Rheumatic Diseases, 2013, 72, A227.3-A228.	0.5	1
652	THU0191â€Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone. Annals of the Rheumatic Diseases, 2013, 72, A228.1-A228.	0.5	1
653	THU0361â€Relationship between MRI and Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Two Years of Adalimumab Therapy. Annals of the Rheumatic Diseases, 2013, 72, A287.2-A287.	0.5	2
654	OP0160â€Response and drug survival of 1st TNF inhibitor in 370 patients with psoriatic arthritis in a real life setting – what is the role of co-medication with methotrexate?:. Annals of the Rheumatic Diseases, 2013, 71, 108.2-108.	0.5	1
655	Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis. Annals of the Rheumatic Diseases, 2012, 71, 899-904.	0.5	107
656	Remission by imaging in rheumatoid arthritis: should this be the ultimate goal?. Annals of the Rheumatic Diseases, 2012, 71, i89-i92.	0.5	26
657	First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology, 2012, 51, 1388-1396.	0.9	112
658	Comparison of features by MRI and radiographs of the interphalangeal finger joints in patients with hand osteoarthritis. Annals of the Rheumatic Diseases, 2012, 71, 345-350.	0.5	56
659	Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 700-706.	0.5	80
660	Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Annals of the Rheumatic Diseases, 2012, 71, 809-816.	0.5	148
661	Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology, 2012, 51, 1378-1387.	0.9	63
662	Pain Management by Pharmacotherapy in Inflammatory Arthritis. Systematic Literature Reviews of the 3e Initiative 2010. Journal of rheumatology Supplement, The, 2012, 90, 1-2.	2.2	0
663	Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Annals of the Rheumatic Diseases, 2012, 71, 518-523.	0.5	130
664	Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial. Journal of Rheumatology, 2012, 39, 1326-1333.	1.0	71
665	MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Annals of the Rheumatic Diseases, 2012, 71, 2002-2005.	0.5	87
666	Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria. Rheumatology, 2012, 51, 1479-1483.	0.9	34

#	Article	IF	CITATIONS
667	Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort. Annals of the Rheumatic Diseases, 2012, 71, 1366-1369.	0.5	46
668	MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 369-373.	0.5	126
669	European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases, 2012, 71, 4-12.	0.5	405
670	Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Annals of the Rheumatic Diseases, 2012, 71, 878-884.	0.5	72
671	Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the Rheumatic Diseases, 2012, 71, 661-667.	0.5	92
672	Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care and Research, 2012, 64, 1699-1707.	1.5	306
673	Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placeboâ€controlled study. Arthritis Care and Research, 2012, 64, 1919-1922.	1.5	19
674	A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 2012, 71, 319-326.	0.5	234
675	Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. Rheumatology, 2012, 51, 1894-1905.	0.9	32
676	Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 1623-1629.	0.5	223
677	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial. Arthritis and Rheumatism, 2012, 64, 2824-2835.	6.7	325
678	Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: Results of a multicenter, randomized study. Arthritis and Rheumatism, 2012, 64, 1272-1282.	6.7	50
679	Golimumab in psoriatic arthritis: Oneâ€year clinical efficacy, radiographic, and safety results from a phase III, randomized, placeboâ€controlled trial. Arthritis and Rheumatism, 2012, 64, 2504-2517.	6.7	171
680	HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1930-1936.	0.5	131
681	Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Annals of the Rheumatic Diseases, 2011, 70, 157-163.	0.5	122
682	2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases, 2011, 70, 896-904.	0.5	831
683	Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Annals of the Rheumatic Diseases, 2011, 70, 47-53.	0.5	589
684	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Annals of the Rheumatic Diseases, 2011, 70, 404-413.	0.5	657

#	Article	IF	CITATIONS
685	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 905-908.	0.5	365
686	Endorsement of Definitions of Disease Activity States and Improvement Scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10. Journal of Rheumatology, 2011, 38, 1502-1506.	1.0	52
687	How to measure disease activity in axial spondyloarthritis?. Current Opinion in Rheumatology, 2011, 23, 339-345.	2.0	51
688	The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine, 2011, 78, 598-603.	0.8	204
689	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism, 2011, 63, 573-586.	6.7	864
690	The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis and Rheumatism, 2011, 63, 1200-1210.	6.7	104
691	Predicting the outcome of ankylosing spondylitis therapy. Annals of the Rheumatic Diseases, 2011, 70, 973-981.	0.5	158
692	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 909-920.	0.5	394
693	Hand osteoarthritis and MRI: development and first validation step of the proposed Oslo Hand Osteoarthritis MRI score. Annals of the Rheumatic Diseases, 2011, 70, 1033-1038.	0.5	87
694	Damage and Progression on Radiographs in Individual Joints: Data from Pivotal Randomized Controlled Trials. Journal of Rheumatology, 2011, 38, 2018-2022.	1.0	20
695	Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 2126-2130.	0.5	32
696	Erosions versus joint space narrowing in rheumatoid arthritis: what do we know?. Annals of the Rheumatic Diseases, 2011, 70, i116-i118.	0.5	35
697	Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Annals of the Rheumatic Diseases, 2011, 70, 1631-1640.	0.5	63
698	MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Annals of the Rheumatic Diseases, 2011, 70, 428-433.	0.5	124
699	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Annals of the Rheumatic Diseases, 2011, 70, 1999-2002.	0.5	71
700	The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Annals of the Rheumatic Diseases, 2011, 70, 25-31.	0.5	1,302
701	A stratified model for health outcomes in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2011, 70, 1758-1764.	0.5	65
702	ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 249-251.	0.5	208

Désirée M Van Der Heijde

#	Article	IF	CITATIONS
703	HLA-B27 and gender independently determine the likelihood of a positive MRI of the sacroiliac joints in patients with early inflammatory back pain: a 2-year MRI follow-up study. Annals of the Rheumatic Diseases, 2011, 70, 1981-1985.	0.5	50
704	Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER. Journal of Rheumatology, 2010, 37, 2237-2246.	1.0	80
705	Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2010, 69, 1465-1470.	0.5	244
706	Spondyloarthritis: state of the art and future perspectives. Annals of the Rheumatic Diseases, 2010, 69, 949-954.	0.5	21
707	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Annals of the Rheumatic Diseases, 2010, 69, 495-502.	0.5	136
708	Repair of erosions occurs almost exclusively in damaged joints without swelling. Annals of the Rheumatic Diseases, 2010, 69, 851-855.	0.5	60
709	Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Annals of the Rheumatic Diseases, 2010, 69, 345-351.	0.5	121
710	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Annals of the Rheumatic Diseases, 2010, 69, 638-643.	0.5	203
711	ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Annals of the Rheumatic Diseases, 2010, 69, 102-107.	0.5	93
712	Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Annals of the Rheumatic Diseases, 2010, 69, 1123-1128.	0.5	110
713	Justification for including MRI as a tool in the diagnosis of axial SpA. Nature Reviews Rheumatology, 2010, 6, 670-672.	3.5	19
714	Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 671-676.	0.5	104
715	Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology, 2010, 49, 812-819.	0.9	183
716	Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 150-154.	0.5	96
717	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2010, 69, 964-975.	0.5	1,429
718	Impact of Age, Sex, Physical Function, Health-related Quality of Life, and Treatment with Adalimumab on Work Status and Work Productivity of Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2010, 37, 385-392.	1.0	77
719	Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 828-833.	0.5	142
720	Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Annals of the Rheumatic Diseases, 2009, 68, 1520-1527.	0.5	719

#	Article	IF	CITATIONS
721	Monitoring anti-TNFÂ treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. Annals of the Rheumatic Diseases, 2009, 68, 1572-1579.	0.5	84
722	Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Annals of the Rheumatic Diseases, 2009, 68, 863-867.	0.5	212
723	Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Annals of the Rheumatic Diseases, 2009, 68, 1113-1118.	0.5	15
724	Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Annals of the Rheumatic Diseases, 2009, 68, 797-804.	0.5	424
725	Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2009, 68, 175-182.	0.5	122
726	Aspects relevant for functioning in patients with ankylosing spondylitis according to the health professionals: a Delphi study with the ICF as reference. Rheumatology, 2009, 48, 997-1002.	0.9	26
727	Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design. Journal of Rheumatology, 2009, 36, 1792-1799.	1.0	38
728	Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria. Journal of Rheumatology, 2009, 36, 1785-1791.	1.0	40
729	Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers. Journal of Rheumatology, 2009, 36, 1769-1784.	1.0	21
730	Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Annals of the Rheumatic Diseases, 2009, 68, 922-929.	0.5	152
731	Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Annals of the Rheumatic Diseases, 2009, 68, 1086-1093.	0.5	404
732	Prevalence of and predictive factors for sustained diseaseâ€modifying antirheumatic drug–free remission in rheumatoid arthritis: Results from two large early arthritis cohorts. Arthritis and Rheumatism, 2009, 60, 2262-2271.	6.7	193
733	The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Annals of the Rheumatic Diseases, 2009, 68, ii1-ii44.	0.5	1,092
734	ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2009, 68, 1811-1818.	0.5	491
735	Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis. Journal of Rheumatology, 2009, 36, 1256-1264.	1.0	47
736	New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Annals of the Rheumatic Diseases, 2009, 68, 784-788.	0.5	498
737	The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Annals of the Rheumatic Diseases, 2009, 68, 770-776.	0.5	731
738	Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Annals of the Rheumatic Diseases, 2009, 68, 1094-1099.	0.5	255

#	Article	IF	CITATIONS
739	Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Research and Therapy, 2009, 11, R124.	1.6	68
740	Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Research and Therapy, 2009, 11, R127.	1.6	357
741	The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Annals of the Rheumatic Diseases, 2009, 68, 777-783.	0.5	2,713
742	Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2009, 68, 18-24.	0.5	772
743	A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: structural outcomes. Clinical and Experimental Rheumatology, 2009, 27, S102-7.	0.4	5
744	Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. Clinical and Experimental Rheumatology, 2009, 27, S108-11.	0.4	58
745	Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelveâ€month, multicenter, randomized, doubleâ€blind, placeboâ€controlled, phase II clinical trial. Arthritis and Rheumatism, 2008, 58, 1299-1309.	6.7	525
746	Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis and Rheumatism, 2008, 58, 1324-1331.	6.7	495
747	Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis and Rheumatism, 2008, 58, 3063-3070.	6.7	461
748	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fiftyâ€two–week, phase III, multicenter, randomized, doubleâ€blind, placeboâ€controlled, parallelâ€group study. Arthritis and Rheumatism, 2008, 58, 3319-3329.	6.7	539
749	Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, doubleâ€blind, placeboâ€controlled, phase III trial. Arthritis and Rheumatism, 2008, 58, 3402-3412.	6.7	512
750	Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Annals of the Rheumatic Diseases, 2008, 67, 489-493.	0.5	116
751	Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Annals of the Rheumatic Diseases, 2008, 67, 511-517.	0.5	127
752	High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Annals of the Rheumatic Diseases, 2008, 67, 212-217.	0.5	269
753	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Annals of the Rheumatic Diseases, 2008, 67, 1360-1364.	0.5	172
754	The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Annals of the Rheumatic Diseases, 2008, 67, 182-188.	0.5	30
755	Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Annals of the Rheumatic Diseases, 2007, 66, 1162-1167.	0.5	674
756	Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp-van der Heijde method for scoring radiographs in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 67, 375-379.	0.5	52

#	Article	IF	CITATIONS
757	How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?. Annals of the Rheumatic Diseases, 2007, 66, 771-777.	0.5	36
758	Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Annals of the Rheumatic Diseases, 2007, 67, 1267-1270.	0.5	80
759	Long-term effects of early treatment in patients with rheumatoid arthritis. Nature Clinical Practice Rheumatology, 2007, 3, 258-259.	3.2	3
760	Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Annals of the Rheumatic Diseases, 2007, 67, 1218-1221.	0.5	50
761	Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 1093-1097.	0.5	126
762	Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2007, 9, R62.	1.6	24
763	Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthritis and Rheumatism, 2007, 57, 133-139.	6.7	111
764	Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis and Rheumatism, 2007, 56, 1846-1853.	6.7	151
765	Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents. Arthritis and Rheumatism, 2007, 57, 639-647.	6.7	177
766	Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis and Rheumatism, 2007, 56, 2698-2707.	6.7	167
767	Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 3928-3939.	6.7	194
768	Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. Journal of Rheumatology, 2007, 34, 862-70.	1.0	97
769	Consensus on a core set of domains for psoriatic arthritis. Journal of Rheumatology, 2007, 34, 1167-70.	1.0	155
770	Magnetic resonance imaging changes of sacroiliac joints in patients with recent-onset inflammatory back pain: inter-reader reliability and prevalence of abnormalities. Arthritis Research and Therapy, 2006, 8, R11.	1.6	51
771	ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases, 2006, 65, 442-452.	0.5	571
772	Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis and Rheumatism, 2006, 54, 1063-1074.	6.7	472
773	Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis and Rheumatism, 2006, 54, 1646-1652.	6.7	220
774	Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 2006, 54, 2136-2146.	6.7	768

#	Article	IF	CITATIONS
775	Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis and Rheumatism, 2006, 54, 3119-3125.	6.7	159
776	The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Annals of the Rheumatic Diseases, 2006, 65, 1038-1043.	0.5	162
777	Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. Annals of the Rheumatic Diseases, 2006, 65, 804-808.	0.5	106
778	Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Annals of the Rheumatic Diseases, 2006, 65, 637-641.	0.5	123
779	Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2006, 65, 423-432.	0.5	188
780	First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2006, 65, 316-320.	0.5	313
781	Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. Journal of Rheumatology, 2006, 33, 234-43.	1.0	91
782	Presentation and analysis of data on radiographic outcome in clinical trials: Experience from the TEMPO study. Arthritis and Rheumatism, 2005, 52, 49-60.	6.7	96
783	Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis and Rheumatism, 2005, 52, 582-591.	6.7	773
784	Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis and Rheumatism, 2005, 52, 1020-1030.	6.7	407
785	Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study. Arthritis and Rheumatism, 2005, 52, 1205-1215.	6.7	187
786	Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis and Rheumatism, 2005, 52, 1756-1765.	6.7	623
787	How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?. Arthritis and Rheumatism, 2005, 52, 1979-1985.	6.7	41
788	Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?. Annals of the Rheumatic Diseases, 2005, 64, 988-994.	0.5	131
789	Psoriatic arthritis imaging: a review of scoring methods. Annals of the Rheumatic Diseases, 2005, 64, ii61-ii64.	0.5	109
790	Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Annals of the Rheumatic Diseases, 2005, 64, 1141-1144.	0.5	129
791	Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Annals of the Rheumatic Diseases, 2005, 64, 1563-1567.	0.5	51
792	Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Annals of the Rheumatic Diseases, 2005, 64, 179-182.	0.5	246

#	Article	IF	CITATIONS
793	Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Annals of the Rheumatic Diseases, 2005, 64, 1582-1587.	0.5	119
794	Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT. Journal of Rheumatology, 2005, 32, 2048-9.	1.0	44
795	Radiographic progression in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2005, 23, S63-8.	0.4	21
796	Development and preselection of criteria for short term improvement after anti-TNFÂ treatment in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2004, 63, 1438-1444.	0.5	188
797	Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order. Annals of the Rheumatic Diseases, 2004, 63, 1601-1604.	0.5	52
798	Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up. Annals of the Rheumatic Diseases, 2004, 63, 1413-1418.	0.5	38
799	Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Annals of the Rheumatic Diseases, 2004, 63, 1046-1055.	0.5	147
800	ls avoidant coping independent of disease status and stable over time in patients with ankylosing spondylitis?. Annals of the Rheumatic Diseases, 2004, 63, 1264-1268.	0.5	13
801	Radiographic progression depicted by probability plots: Presenting data with optimal use of individual values. Arthritis and Rheumatism, 2004, 50, 699-706.	6.7	69
802	How to diagnose axial spondyloarthritis early. Annals of the Rheumatic Diseases, 2004, 63, 535-543.	0.5	533
803	Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet, The, 2004, 363, 675-681.	6.3	1,662
804	Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. Journal of Rheumatology, 2004, 31, 125-32.	1.0	95
805	Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatology International, 2003, 23, 61-66.	1.5	707
806	Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: Evaluation of a new scoring system. Arthritis and Rheumatism, 2003, 48, 1126-1136.	6.7	377
807	Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis and Rheumatism, 2003, 48, 3230-3236.	6.7	707
808	Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality?. Annals of the Rheumatic Diseases, 2003, 62, 519-525.	0.5	199
809	Costs of ankylosing spondylitis in three European countries: the patient's perspective. Annals of the Rheumatic Diseases, 2003, 62, 741-747.	0.5	60
810	International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2003, 62, 817-824.	0.5	353

#	Article	IF	CITATIONS
811	Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Annals of the Rheumatic Diseases, 2003, 62, 732-740.	0.5	100
812	Assessment of enthesitis in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2003, 62, 127-132.	0.5	531
813	Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Annals of the Rheumatic Diseases, 2003, 62, 20-26.	0.5	480
814	Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Annals of the Rheumatic Diseases, 2002, 61, 429-437.	0.5	182
815	How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. Arthritis and Rheumatism, 2002, 47, 215-218.	6.7	132
816	Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis and Rheumatism, 2002, 46, 913-920.	6.7	125
817	Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthritis and Rheumatism, 2002, 47, 242-248.	6.7	82
818	Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis. Arthritis and Rheumatism, 2002, 46, 2847-2856.	6.7	159
819	Evaluation of the smallest detectable difference in outcome or process variables in ankylosing spondylitis. Arthritis and Rheumatism, 2002, 47, 582-587.	6.7	56
820	Assessment of fatigue in patients with ankylosing spondylitis: A psychometric analysis. Arthritis and Rheumatism, 2002, 47, 8-16.	6.7	138
821	Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. Journal of Rheumatology, 2002, 29, 2306-12.	1.0	64
822	Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Annals of the Rheumatic Diseases, 2001, 60, 353-358.	0.5	181
823	Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis and Rheumatism, 2001, 44, 180-185.	6.7	222
824	Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis and Rheumatism, 2001, 44, 1876-1886.	6.7	561
825	Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2001, 60, 1033-1039.	0.5	164
826	How to read radiographs according to the Sharp/van der Heijde method. Journal of Rheumatology, 2000, 27, 261-3.	1.0	499
827	Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. Rheumatology, 1999, 38, 1213-1220.	0.9	103
828	How to read radiographs according to the Sharp/van der Heijde method. Journal of Rheumatology, 1999, 26, 743-5.	1.0	342

#	Article	IF	CITATIONS
829	Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. Journal of Rheumatology, 1999, 26, 951-4.	1.0	193
830	Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. Journal of Rheumatology, 1999, 26, 980-4.	1.0	212
831	Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. Journal of Rheumatology, 1999, 26, 997-1002.	1.0	40
832	Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. Journal of Rheumatology, 1999, 26, 1003-5.	1.0	47
833	Quality of life in rheumatoid arthritis. Rheumatology, 1997, 36, 884-888.	0.9	161
834	Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. Journal of Rheumatology, 1997, 24, 2225-9.	1.0	159
835	Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. , 0, .		1